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Abstract 
Herpes simplex virus (HSV) type 2 is the cause of one of the most wide-spread human infections 
in the world, affecting millions of people and circumventing all past attempts to cure or prevent 
infection. One of the biopharmaceutical companies involved in HSV-2 vaccine development, 
Sanofi Pasteur, has developed a candidate vaccine based on a live, replication-deficient HSV-2 
virus. The “ACAM529” strain is subject to two gene deletions and requires a complementary 
African Green Monkey Kidney (Vero) cell line (AV529-19) to replicate. A bottleneck exists in 
the production process which is hypothesized to be the result of virus particles being directed 
towards both cell-cell and cell-substrate (adherent surface) junctions. The overarching goal of 
this work was to determine if some mature virus particles localize and egress at substrate surface 
junctions, becoming inaccessible to traditional extraction methods.  
To test the hypothesis, an alternate titration method was first developed using induced 
fluorescence end-point dilution assay with a spectrofluorometer. The second stage of the 
research involved the use of immunofluorescent staining to locate viral proteins within infected 
cells in order to inform future process optimization. Mature virus particles were of particular 
interest and the co-localization of two essential proteins was used to determine their location. A 
pseudo co-culturing protocol was then developed using cell culture inserts. This system was used 
in an attempt to determine the extent to which viral budding occurred towards the substrate. 
The fluorescence which the HSV2012-121 Vero cells displayed on infection with ACAM529 did 
not allow for effective differentiation between infected and uninfected cells. Treatment of the 
cells with Sodium Butyrate (2mM NaBu added at the time of seeding) resulted in a 16.93-fold 
difference between infected and uninfected cells’ fluorescence. Immunofluorescent staining of 
two virus proteins to determine their co-localization was not successful. Evidence pointed to 
bleeding of the signals between the 488 and 405nm channels, as well as to a lack of capsid 
staining in the presence of a tegument of envelope layer. Nevertheless, individual glycoprotein 
stains were found to be effective and provided good insights into the virus’ behaviour. Lastly, the 
AV529-19 Vero cells were shown to adhere effectively to insert membranes and form confluent 
monolayers. Staining and counting of the resulting plaques was used to establish a required 
initial infection titer between 8.3x10
4
 and 1.2x10
6
 PFU/mL for future cell insert experiments. 
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Chapter 1 – Introduction 
Herpes simplex virus (HSV) type 2 is the cause of one of the most wide-spread human infections 
in the world, affecting millions of people and circumventing all past attempts to cure or prevent 
infection. While its most common symptoms are mild compared to many other viral infections, 
especially those transmitted through intimate contact, it is known to cause severe lesions, 
blindness, and even death in vulnerable individuals. The serious harm that HSV can cause to 
immunocompromised populations coupled with the virus’ ability to establish life-long recurrent 
infections are, in large part, the driving force behind HSV research. Developing a vaccine for 
HSV has been the subject of extensive efforts with intellectual, humanitarian, and financial 
incentives to continuing on this path in spite of past failures.  
One of the biopharmaceutical companies involved in HSV-2 vaccine development, 
Sanofi Pasteur, has developed a candidate vaccine based on a live, replication-deficient HSV-2 
virus. The “ACAM529” strain is subject to two gene deletions and requires a complementary 
African Green Monkey Kidney (Vero) cell line (AV529-19) to replicate. Although a process 
exists for the amplification and recovery of the virus, its labile nature causes significant losses in 
yield. It has been reported that HSV-2 virus particles do not exit their host cells indiscriminately, 
but are instead directed towards both cell-cell and cell-substrate (the surface to which the cells 
adhere) junctions [1]. The hypothesis of my work was that these cells could be contributing to 
the production bottleneck which occurs at viral harvesting. 
A mojor goal of this work was to determine if some mature virus particles localize and 
egress at substrate surface junctions, becoming inaccessible to traditional extraction methods. To 
test this hypothesis, three objectives were set. First, a rapid and reliable quantification method 
was sought. To enhance current practices a novel cell line was developed based on AV529-19 
which contained a reporter green fluorescent protein gene under a virally inducible promoter. 
This cell line is referred to as HSV2012-121.  The second objective of this work was to 
determine the intracellular location of the virus through the co-localization of multiple viral 
proteins present in fully matured virus particles. The final objective of this work was to develop 
a culturing method that would allow the preferential viral egress to be studied. 
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A summary of current down-stream processing (DSP) technology for purification of virus 
particles is allotted an entire chapter of this thesis (Chapter 3) due to the importance of this topic 
to virus production processes. While the focus of the research did not relate to the DSP of the 
virus, the requirements and limitations of viral purification for vaccines influenced the methods 
used.   
Viral titration is required for any production process, and determining viral titer is often a 
tedious and time-consuming process. Plaque assays are currently the most reliable and accurate 
method for enumeration of the ACAM529 virus but are time consuming and highly dependent on 
operator experience. Chapter 5 describes the use of the HSV2012-121 fluorescing Vero cell line 
to establish an alternative enumeration assay.  
Chapter 6 aimed to determine the intracellular localization of mature virus particles in 
infected cells. The replication of HSV involves a complex cascade of viral gene expression and 
the creation of a host of gene products. Of these, several essential proteins were selected and 
tagged using direct and indirect immunofluorescent staining. Antibodies against glycoproteins 
involved in cell entry, fusion, and cell-to-cell transmission (a-gB, a-gE, a-gC, and a-gD) as well 
as major structural proteins (a-ICP5, a-ICP27, and a polyclonal antibody against late structural 
proteins of HSV-2) were investigated as the proteins targeted by them are all essential for 
infectious mature virus particles. 
In Chapter 7, a culturing and infection technique was developed to determine the fraction 
of progeny virus particles which exits the cell towards the surface on which the cells are 
growing. Cell culture inserts allowed two separate Vero cell monolayers to interact without 
direct contact. First, the efficacy of the cell culture insert as a substrate for the genetically 
modified Vero cells was established. The pseudo co-culturing protocol was then used to study 
the extent to which the virus particles bud downwards into their substrate rather than in any other 
direction (including cell-to-cell transmission). 
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Chapter 2 – Literature Review 
2.1 Introduction to the herpes simplex virus 
2.1.1 Epidemiology and Pathogenicity 
The Herpesviridae family of viruses is one of the most successful animal pathogens on Earth if 
success of such entities is measured by their prevalence in the host organisms’ population. If 
measured by their ability to adapt to different hosts or longevity of infection herpes viruses are 
still near the very top in terms of viral success. Almost every animal species investigated for 
members of the Herpesviridae family has shown to have at least one such virus adapted to it [2]. 
In most cases this infection last for the host’s entire life and spreads easily to other members of 
its population. Humans can be infected with several different Herpesvirus members but the most 
common are infections of herpes simplex viruses (HSV-1 and HSV-2 for types 1 and 2 
respectively). HSV-2 is the research focus of this work but its many similarities to HSV-1 and 
the very much linked nature of the research of these two viruses necessitates the inclusion of 
HSV-1 in this literature review.  
Some studies have shown that as many as 85% of adults have come into contact with 
HSV-1 and 22-25% with HSV-2 and are therefore sero-positive (meaning tests for anti-HSV 
antibodies return positive results indicating exposure and possible infection) [3, 4]. In the case of 
HSV-2, the rate of sero-prevalence has increased by 32% in the 1990’s alone [4] and more at-
risk populations (such as sexually transmitted infection (STI) clinic attendees) have been found 
to be 30-50% sero-positive [4]. One research paper estimates Worldwide infection numbers for 
HSV-2 at 536 million, with 23.6 million newly infected individuals just in 2003 [5]. The 
percentages are so high that when standard STI blood panels are conducted, HSV is usually not 
included. Unless overt symptoms appear, it’s almost impossible to differentiate between 
someone simply exposed to the virus and an asymptomatic non-shedding infection. 
HSV-1 is the virus most commonly responsible for “cold-sores”, the small recurring 
blisters or lesions usually found around the mouth and nose. HSV-2 mostly presents on the 
genitals and is most commonly contracted through sexual contact. It also presents as blisters or 
sores that burst within days of an outbreak and take days or weeks to heal [6, 7]. It is possible for 
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HSV-1 to infect the genitals and for HSV-2 to cause an orofacial infection and these cases are 
becoming more common, potentially pointing to changing sexual practices world-wide [8, 9].  
These blisters are the direct result of cell death mediated by the virus, as well as the 
body’s inflammatory response to the infection [7]. A fever may also accompany the outbreak, 
especially during primary infection. For both viruses, the lesions are painful and irritating while 
also representing major sites of viral “shedding” (release of infectious virus particles), which can 
transmit the infection [6]. Once primary infection has occurred HSV particles (both type 1 and 2) 
are then transported through nerve axons and establish a latent infection in dorsal root ganglia 
(vagal, trigeminal, or sacral, depending on the site of initial infection) [7]. The exact mechanism 
by which the virus enters a non-replicative latent infection state has not yet been determined [7]. 
Once there, the virus will re-activate throughout the hosts’ life. This occurs most often in 
response to stress, fever, tissue damage and any other event leading to a weakened host immune 
system [2, 3, 7].  
Both viruses can shed and be transmitted even when the infected individual is 
asymptomatic. All that is required is contact between a shedding site of the infected individual 
and the mucosal layer or abrasion in the skin of another [7]. This is of vital importance since 
only about 10-25% of individuals infected with HSV-2 ever show symptoms and many 
transmissions occur without any previous history of “Genital Herpes” [10]. Symptomatic 
individuals are more likely to be shedding at any given point in time (20.1% of days tested, with 
43% of those days being symptomatic) than asymptomatic individuals (10.2% of days tested) 
[10]. Given that a large number of individuals infected with HSV-2 do not know they have it and 
that most are still infectious, it is no surprise that it continues to be the most common STI in 
humans.  
2.1.2 HSV-2 Lifecycle (Cycle of Infection) 
2.1.2.1 HSV-2 Morphology 
The HSV-2 particle is fairly complex in its morphology and is composed of four major 
components: the core, the capsid, the tegument, and outer envelope (Figure 1). The entire particle 
is roughly 180-200nm in size and is generally spherical in shape [2]. At the very core of any 
virus’ structure is the viral nucleic acid. The ultimate goal of any virus is to deliver this nucleic 
acid to the nucleus of a host cell and it is therefore very well protected. In the case of the HSV-2 
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virus, the genetic information is stored as linear double-stranded DNA with a genome length of 
approximately 1.55x10
5
 bp [11]. This genome codes for 74-84 distinct proteins, at least three of 
which are coded for twice. The core is toroidal in shape (resembling a donut) with the DNA 
wrapped around a proteinaceous core [12, 2].  
 
Figure 1: HSV-2 virus particle structure (diameter = ~200nm) 
The DNA-containing core of the virus is surrounded by a protein capsid. This capsid is 
icosahedral in shape and consists of 162 hexagonal capsomeres (geometric shape with 20 sides 
composed of 162 hexagonal subunits) [12, 2, 13]. It makes up for over half of the virus particle’s 
size at about 95-105nm. Over top of the capsid there is a tegument layer composed primarily of 
lipids and some proteins. These lipids are acquired from the cellular membranes of the virus’ 
original host cell. The proteins in the tegument enter the host cell at the same time as the capsid. 
They are required early in the infection process and can be detected within the cell cytoplasm 
immediately after viral attachment [14, 2]. The tegument layer is bounded by an outer envelope 
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that is acquired from the virus’ original cell. This envelope is stubbed with viral glycoproteins 
that aid in new host cell location, viral attachment, and fusion. 
The morphology described above for HSV-2 is shared by all Herpesviruses [12]. The 
variation occurs in the specific proteins and DNA sequences of the viruses. HSV-1 and 2 share 
many of the same glycoproteins and most of their genetic information to the point where a study 
on the exact size of the HSV-2 genome led to the re-evaluation of what we know about HSV-1’s 
[11]. Luckily, there are differences in protein structure between the HSV-1 and HSV-2 which 
allow for exact clinical diagnosis of the herpes simplex type[15].  
2.1.2.2 Primary Infection 
2.1.2.2.1 Fusion and Entry 
A herpes simplex virus infection is transmitted through direct intimate contact between an 
infected and shedding individual’s mucus layer and that of an uninfected individual. Co-infection 
of HSV-1 and 2 is not uncommon and some studies have found that it may actually aid in 
preventing clinical presentation of symptoms from HSV-2 [16]. Since direct contact of mucus 
layers is required for infection, the likelihood of transmission through casual contact is minimal. 
There have, however, been cases of medical professionals acquiring HSV infections through 
lesions on their hands while working with HSV sero-positive patients [17]. The spread of HSV-2 
is not guaranteed on intimate contact with a shedding individual, with a median number of 40 
sexual acts required for infection to pass on in serodiscordant partners i.e. where one partner is 
infected and one is not [18].  
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Figure 2: Schematic of fusion and entry of HSV-2 into host cell (not to scale) 
In order to infect a host cell, the HSV-2 particle must first latch on to or adhere to the 
cell’s outer membrane (Figure 2). Fusion of the particle occurs through the actions of 
glycoproteins on its outer membrane rather than with fusion peptides as is observed in other 
viruses (like influenza or HIV) [19]. Glycoproteins B, D, H, and L (gB, gD, gH, and gL, 
respectively) are all involved in this mechanism. gD has been shown to enable entry of the virus 
whether it is expressed on the viral membrane or added in soluble form, indicating its role as a 
trigger for fusion to a viable cell rather than participating in the fusion itself [20]. This is most 
likely through induced conformational changes, which allow the other three glycoproteins to fuse 
to nearby receptors. Glycoprotein C has also been found to serve in this role in some cases 
making it a fifth, nonessential, glycoprotein involved in fusion [17].  
The receptors implicated in HSV fusion are nectin-1, Herpesvirus entry mediator (or 
HVEM), and 3-O sulphated heparin sulphate [17, 20, 21]. All of these are found on the surface 
of human cells but are significantly different in structure and purpose. Nectin-1 is a cellular 
adhesion molecule that is involved in the formation of epithelial cell junctions. It also plays a 
role in epithelial cell migration and polarization [22]. HVEM is a tumor necrosis factor receptor 
implicated in certain types of lymphoma in addition to mediating HSV entry [23]. Heparin 
Sulfate is an important proteoglycan which influences cell growth and other physiological 
changes [24]. 
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Initial contact with a HSV-implicated surface receptor is not necessary for binding of the 
virus particle however. The particle is quite likely to come into contact with structural elements 
of the cell’s outer membrane (filopodia cell extensions - dense clusters of actin filaments - for 
example). In these cases the HSV-2 particle has been shown to engage a mechanism that moves 
them along the cell’s outer surface referred to as “surfing” [25]. Not only that, but the virus 
particle is also able to increase the number of filopodia  on the cell’s outer surface by activating 
key hydrolase enzymes (GTPases). HSV-2 gB also plays a role in surfing [26]. 
Glycoproteins H and L form a heterodimer on the virus particle’s envelope and interacts 
with gB on fusion to a cell membrane [17, 21]. gD signals the availability of a compatible 
receptor and initiates conformational changes in  the gB and gH/gL “fusion apparatus” which 
ultimately result in fusion of the virus’ outer membrane to the host cell’s [21]. The exact manner 
in which this occurs is not well understood [27]. The combination of these glycoproteins occurs 
only at the onset of fusion and they don’t exist as a complex on the virus’ membrane. Once the 
two membranes have been brought into contact by the fusion glycoproteins, their lipids mix and 
a “hemifusion intermediate” is formed[28]. The mixing eventually allows a pore to form through 
which the contents of HSV-2’s outer membrane enter the cytoplasm of the host cell, completing 
the fusion and initiating the viral infection.  
The fusion process described above is the most common method for HSV entry into a 
host cell. However, the virus also has the ability to enter certain cell types through endocytosis 
[27]. In this case the fusion occurs at a vesicular membrane and involves all of the same 
glycoproteins. This method is favoured by the virus when infecting CHO, HeLa, RPE, and 
certain epithelial cells while regular fusion occurs for Vero and Hep2 cells [29, 27]. gD is 
suspected in playing a role in selecting which entry method is used. It has been shown to down-
regulate the nectin-1 receptors on the surface of cells which are entered via endocytosis [30]. 
2.1.2.2.2 Viral Gene Expression and Viral Replication 
The Herpesvirus begins the process of altering the host cell’s mechanisms for its eventual 
reproduction as soon as it becomes initially attached. Interaction between key glycoproteins (gD 
then gB) causes a phosphorylation of protein kinase B (Akt) and release of Ca
+
 ions in the 
vicinity of the plasma membrane [31]. This in turn starts a signaling chain reaction which affects 
not only entry of the viral capsid, but also its transport to the nucleus of the cell. The viral 
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proteins and capsid are transported throughout the cell by first re-purposing cellular messaging 
mechanisms, most notably the Ras, Raf, MEK, and ERK pathways [32]. HSV-2’s ribonucleotide 
reductase protein ICP10 has been found to mediate, at least in part, the activation of these 
pathways and prevention of cell death from apoptosis [33, 32]. Other viral proteins entering from 
the tegument layer induce the shutoff of host cell protein production and participate in the 
transport of the capsid along microtubules towards the nucleus [17, 34].  
 
Figure 3: DNA replication and capsid assembly of HSV-2 in host cell 
By the time the capsid has reached a nuclear pore and entered the nucleus (Figure 3), the 
host cell’s structure is already in the midst of its alteration. Organelles such as the Golgi 
apparatus and trans-Golgi network as well as structural elements like the microtubules of the 
cytoskeleton are all altered to fit the needs of the virus [35, 36, 37]. While this is a common 
feature of Herpesviruses, the exact purpose of many of the alterations is unknown [37]. The 
capsids themselves have been found to accumulate around the nuclear membrane indicating that 
their dissolution is not necessary for the genetic material to enter the nucleus [38, 39]. Once the 
DNA has entered the nucleus, a series of events occurs which leads to the efficient replication of 
the viral DNA [2]. By this stage in the infection, the viral DNA’s shape has changed from linear 
to circular [40] and there is strong evidence that the DNA repair mechanisms of the host cell are 
then recruited to repair any damage suffered by the viral DNA [41, 42].  
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The HSV-2 DNA localizes at particular nuclear structures, aka “Nuclear Dot 10”, within 
the nucleus while the viral protein ICP0 breaks these structures down [2, 43, 44]. The point at 
which this localization occurs in the infection is still not well understood and there is some 
evidence that the Nuclear Dot 10 sites localize to viral DNA and not the other way around [45]. 
Viral proteins involved in replication are assembled around these same areas, forming small 
occlusions. The actual replication of the virus occurs within these occlusions (now called 
“replicative compartments”), resulting in their expansion and collusion (combining together to 
form fewer large occlusions) [46, 44]. Eventually the occlusions grow to fill the whole nucleus, 
marginalizing the host DNA in both space and functionality and increasing the host cell nucleus’ 
size [47]. 
Expression of the viral genes begins once the genetic information has entered the nucleus 
and follows a very structured chronological order. It is referred to as a “cascade” of expression in 
much of the literature [48, 49, 50]. This cascade is broken into five different stages or groups of 
proteins expressed in a similar fashion: α/immediate-early genes, β1/early-early genes, β2/late-
early genes, γ1/leaky-late genes, and γ2/true late genes [11, 2]. These gene expression categories 
reflect the order in which the gene expression peaks within the host cell. Many viral proteins can 
be found within the cell as early as 3 hours post infection (hpi) while only reaching peak 
concentration at around 6 or 12hpi and being classified as a γ gene [51]. In total, the genome of 
HSV-2 codes for at least 84 proteins, and 16-17 microRNA’s. 
α genes are coded in such a way as to not require prior gene expression for their own 
activation and code for products regulating gene expression. The gene expression that follows 
relies on the α genes to initiate, with each β gene having its own set of requirements. β genes 
code for products with a wide array of functions, most of which deal with the synthesis and 
folding of viral DNA. γ genes are in general expressed later than β genes and their products 
require both α and β genes, and only begin expressing after the start of viral DNA synthesis. 
They code for products directly involved in packaging viral DNA for entry into capsids, 
glycoproteins, and other components involved in the final assembly and egress of the HSV-2 
progeny particles [2]. 
Capsid proteins are not produced in the nucleus but rather translocated in from their 
synthesis sites in the cell cytosol [49]. The capsid is then assembled within the nucleus around a 
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scaffold composed of UL26.5 gene product which is then replaced by packaged viral DNA. 
Assembled progeny virus particles consisting of a capsid and replicated viral DNA begin to 
accumulate within the infected cell as early as 6hpi. The accumulation continues at an 
exponential rate until 12hpi and then becomes linear until well into the infection (as late as 
36hpi) at which point the host cell is likely already dead [2]. The other components of the final 
virus particle are attained on the way out of the host cell, as discussed below. 
2.1.2.3 Nuclear Egress and Envelopment 
 
Figure 4: HSV-2 nuclear egress, envelopment, and egress from host cell 
Once assembled, newly formed and immature virus particles (immature since they lack a 
tegument layer or viral envelope) in the nucleus face the challenge of getting through the nuclear 
membrane (Figure 4). Most transport in and out of the nucleus occurs by translocation through 
nuclear pores [52, 53] as the two layers of membrane and chromatin/lamin structures at the inner 
nuclear membrane make it a strong barrier. Unfortunately, viral capsids are too large to be 
transported through a nuclear pore once assembled and the HSV-2 particles’ egress requires 
more specialized mechanisms [54]. The exact mechanisms of egress has been the subject of no 
small amount of scientific debate and the currently best-supported model is one of membrane 
envelopment at the inner nuclear membrane, subsequent de-envelopment at the outer nuclear 
membrane, and a final envelopment prior to exit from the cell [49, 55]. Much of this process is 
consistent throughout the Herpesviridae family with mostly the same proteins coded for and 
involved [49, 56].  
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The first stage of the particles’ movement through the nuclear membrane is the formation 
of a complex between the products of the viral genes UL31 and UL34. This complex is integral to 
the phosphorylation of the nuclear lamin for the creation of budding sites on the inner nuclear 
membrane [57, 58] and is referred to as the Nuclear Egress Complex (NEC). The exact 
mechanisms performed by the complex are not well understood but it has been proven that both 
UL31 and UL34 gene products are necessary for the first (or primary) envelopment step of the 
HSV egress process [55]. The structure of the host chromatin is also disrupted at the sites of 
budding [59] in order to provide easier access to the inner membrane. From there, the NEC has 
been found to recruit viral glycoproteins gM, gB, gH, gL, and gD to the inner membrane of the 
nucleus [60] but the exact mechanisms by which they assist egress has not been determined. 
What has been observed is a drastic change in the shape of the nuclear membrane as it “becomes 
extended and tends to fold in on itself – a phenomenon known as membrane reduplication” [2]. 
With the completion of primary egress, the enveloped virus particle reaches the 
perinuclear space between inner and outer nuclear membranes. The process by which the virus 
particle escapes into the cell cytoplasm is one of de-envelopment. The membrane it has acquired 
from the inner nuclear membrane fuses with the outer nuclear space with the aid of glycoproteins 
B and the gH/gL complex [61]. The exact mechanism of this fusion is not known, but given the 
similarity of glycoproteins involved to viral entry to the cell it may be that the processes are 
similar. The receptors involved on the inside of the outer nuclear membrane must be defined to 
further understand this process [2]. In addition, there is also a distinct possibility that another 
nuclear egress pathway exists since HSV-2 particles with gB, gH, and gL deletion mutations can 
still be readily found in the cytoplasm [62, 63, 64]. It has been hypothesized that egress through 
nuclear pores (which become enlarged during the infection) allows unenveloped viral capsids to 
exit the nucleus [65]. While this would explain the presence of naked capsids in the cytoplasm, it 
would also require active transport on the part of the nuclear pores of which there is no evidence. 
No studies have shown the presence of nuclear RNA and proteins in the cytoplasm that would 
indicate passive transport through nuclear pores (spilling out of all material in other words) and 
several studies have shown nuclear integrity is maintained in spite of shuttling of viral proteins 
between the cytoplasm and the nucleus [66, 67]. 
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Once virus particles have budded into the cytoplasm they must acquire their tegument 
and envelope in order to reach maturity and be infectious. Tegumentation of the capsids begins 
either at the capsid itself, at the future location of envelopment, or both [68]. There is evidence of 
both occurring within infected cells, and so a simultaneous two-site process with the required 
components gathering and assembling at both sites may be required [49]. The inner-most part of 
the tegument of HSV has been found to contain the protein product of the UL36 gene, and be 
anchored directly to the capsid [69]. If this is the case, then the UL36 must interact with all other 
tegument components as the process of envelopment moves forward [49]. The importance of a 
given glycoprotein to the tegumentation process varies, with the absence of gE and gM resulting 
in no reduction in infectious viral titer [70] while 
–
gD and 
–
gE mutants show defects and loss of 
titer [71]. 
The exact location of envelopment is difficult to gauge given the rearrangement of host 
cell organelles and structures during HSV-2 infection [2, 14]. Sites of envelopment have been 
identified by the presence of various markers which indicate the origin of a given membrane 
[14]. The acquisition of an envelope seems to occur close to the Golgi apparatus and there is 
strong evidence that the vesicles involved in the budding belong to the Golgi as well [72, 73]. At 
the time of budding these vesicles are found in Trans-Golgi Network-like organelles, as 
identified by morphological indicators, multiple TGN markers [74, 75], and the composition of 
the envelope of budded virus particles [76].  
While the nature of the membranes involved and information on the relative importance 
of certain glycoproteins have shed light on the secondary envelopment process, the plethora of 
viral components involved, and redundancy in many of these proteins, have made it difficult to 
fully characterize this process [49, 14, 68, 75, 77]. The research is further complicated by the 
existence of both untegumented capsids and enveloped capsid-less teguments (known as L 
particles) and envelopes in HSV-2 infected cells [68].  
2.1.2.3.1 Virus Budding and Cell-to-Cell Transmission 
With the successful completion of secondary envelopment, mature virus particles (capsid, 
tegument, and envelope fully formed) are enclosed within a Golgi-derived excretory vesicle and 
ready to be transported to the cell’s plasma membrane [1, 49]. From there, the virus particles 
must find their way out of the host cell for the infection to propagate. Virus particles can bud out 
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of the cell completely, becoming “extracellular free particles” [78] that can then attach to a new 
host cell. However, this is not the preferred method for HSV [79]. As mentioned earlier, HSV 
primary infections occur in mucosal layers that are made up of highly polarized epithelial cells 
[1]. There is strong evidence that in this kind of system, HSV prefers to spread directly through 
cell-to-cell junctions [78, 1, 35]. This results in lesions forming rather than a more diffuse 
infection patterns.  
This mechanism of spread is attributed mainly to a heterodimeric glycoprotein composed 
of gE and gI [35, 80]. gE has been found to accumulate first at the TGN in early infection [72, 
81, 80], and then at cell-to-cell junctions towards late infection  [81]. At the TGN, both gE and gI 
interact with sorting machinery [79], thereby facilitating the directed shuttling of virus particles 
to either cell junctions or basolateral surfaces (those surfaces facing the surface to which the cells 
are attached) by the TGN vesicles [82]. The pattern of localization displayed by gE/gI coinciding 
with that of the TGN vesicles was confirmed through simultaneous tracking of gE/gI with cell 
TGN protein TGN46 [72, 79]. Viral mutants lacking either gE or gI have been found to lose their 
ability to infect in a cell-to-cell manner, while retaining their ability to infect cells through 
attachment to the outer membrane [81]. In these cells, the budding location of the virus becomes 
random, just as it seems to do when infecting non-polarized cells and in low-confluence cell 
cultures (where no cell junctions could form) [82]. 
The role of the gE/gI complex once the virus particles have reached cell-to-cell junctions is not 
well understood, but there is evidence that it may bind with junction-associated proteins, thereby 
acting as a receptor-binding protein (like gD is for extracellular attachment) [81, 72]. Other 
glycoproteins associated with direct cell-to-cell spread of HSV include gB [83], gD[63], and 
gH/gL [62], a cast very similar to that which is required for extracellular entry. This overlap 
suggests that the two methods for entry of the virus into an uninfected cell are not dissimilar in 
mechanism. Whichever method a particular virus particle utilizes, once it has infected a new host 
cell the primary lifecycle is complete and the infection moves forward. 
2.1.2.4 Latent Infection 
As mentioned much earlier, while initial infection and most symptoms present on mucosal 
layers, HSV-2 is neurotropic and capable of establishing a latent infection in host nerve ganglia 
[84]. The connection between recurring mucosal infections was not attributed to latency in the 
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nerves until 1929, when it was proposed by Ernest W. Goodpasture [85]. HSV was not isolated 
from nerve tissue until over 40 years later and only recently have we come to understand this 
process well enough to start harnessing it for gene therapy vectors. While the work conducted in 
this thesis is strictly with epithelial cells and non-latent HSV-2, a discussion of the lifecycle of 
this virus is not complete without at least a cursory summary of the latent stage. 
Once the first replication cycle has been complete, some virus particles attach to axon 
terminals of sensory neurons beginning the process of latent infection [84, 9]. The ganglion to 
which these nerves are connected depends on the location of the primary infection. In the case of 
genital HSV-2 infection, latency is established in the dorsal root ganglion (near the bottom of the 
spinal cord) [9]. The tegument and viral capsid are transported together in retrograde fashion 
along the axons to the neuronal soma and infect the nerve cell as it would any other. During this 
process, the majority of the tegument proteins are lost, and the exact proteins which remain have 
yet to be determined. In fact, the deletion of no single gene coding for a viral protein has been 
found to completely stop latent infection in animal models [86, 87]. Whatever tegument proteins 
remain join the viral capsid and they are transported rapidly along microtubules by host 
molecular transport machinery [88].  
Once HSV-2 capsids reach the nerves’ nuclei, they have been found to express their full 
spectrum of genes for the first 24-72 hours (in animal models), after which they become 
repressed [89, 90]. The presence of active virus particles in infected ganglia remains constant for 
the first 7 days before dropping off, which has been found to coincide with the increase in 
immune response elements such as CD8
+
 T cells [91, 92]. The exact process by which the virus 
becomes latent is not well understood, but it seems that the lack of expression of α genes plays a 
role in interrupting regular viral replication. Whether this is because the host nuclei lack ability 
to transcribe α genes [93, 94], the expression is repressed by the virus’ own encoded latency 
controls [95], or (knowing what we know about HSV-2) a complex inter-related combination of 
factors, the virus becomes embedded in the nerve ganglia permanently and latent infection is 
established. 
In its latent state, the virus exists as “non-integrated, nucleosome-associated episome in 
the host cell nucleus” [96]. This means the viral genetic information is preserved as a closed-
circle DNA molecule separate from the host chromosomes and which can replicate separately 
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from the host DNA. No genes are expressed from the viral genome barring the latency-
associated transcript (LAT), the expression of which has been found to be regulated by post-
transcriptional modification rather than DNA methylation [84, 96]. The LATs most common 
form is 2.0kbp long and has been found to be an exceptionally stable intron [97]. A further 
spliced and stable 1.5kbp species has also been found in neuronal cells [98]. While its exact 
functions have not been determined, studies have shown its involvement in both establishing 
latent infection and reactivation [99, 100]. 
Reactivation of the virus can occur due to local stimulus, such as direct damage to 
latently infected cells, but is usually associated more with systemic stimulus. In most cases the 
stimulus is a stressor of one kind or another, with emotional stress and hormonal imbalance 
being among the most common. Once triggered, reactivation occurs in a small number of the 
infected nerve cells and the virus is very quickly transported back down to the peripheral tissues. 
Studies have shown that the envelope/tegument components of the virus are transported 
separately from the capsid components along the axons [101, 102]. In most cases, the secondary 
infection will occur very close to the location of first exposure and the nature of the reactivation 
will vary based on various factors (state of the host immune system for example). Reactivation is 
often asymptomatic but the host remains infectious as virus particles “shed” from microscopic 
lesions [2]. 
2.1.3 Vaccine Development to Date 
The search for an effective HSV-2 vaccine has been underway for many decades now without 
any definitive breakthroughs being accomplished [18]. The difficulty of vaccinating against 
HSV-2 is two-fold. Firstly, as mentioned previously, many transmissions occur without prior 
knowledge of any infection by either partner in a given sexual relationship. Whether the initial 
infection is in truth unknown to either party is difficult to ascertain given the prevalence of 
asymptomatic, but infectious, carriers and the stigma associated with the infection. The virus’ 
lifelong prognosis means that there is always a huge pool of hosts who can pass it on through 
carelessness or ignorance.  
The second major difficulty comes from the virus’ innate ability to circumvent the host’s 
immune system. While both the innate and adaptive portions of the immune system effectively 
combat the infection in immune-competent individuals, they are unable to prevent latent 
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infection by the virus or re-activation from this latent state. Built-in mechanisms exist which 
induce cell death in the event of viral infection. Both HSV-1 and 2 have been shown to mediate 
the cell apoptosis which delays cell death until the virus has had time to replicate [103]. Once 
initial infection has occurred, HSV-2 spreads almost exclusively by cell-to-cell transmission, 
reducing the likelihood of the particles becoming inactivated by neutralizing antibodies [17, 78, 
104].  
There is growing evidence that shedding of the virus occurs simultaneously at various 
regions of the genital tract and that shedding is almost 100 times more likely at a given site if 
shedding is occurring nearby [105]. Either the virus reactivates simultaneously from various 
locations in the nerve ganglion, the virus is able to spread cell-to-cell even when subverted to a 
subclinical level of infection, or both are occuring. In any case it is clear that HSV-2’s various 
adaptations have left it more than capable of outwitting the immune system and persisting in 
spite of the presence of specialized antibodies and T cells. 
The search for an effective prophylactic or therapeutic vaccine against HSV-2 has not 
been given up despite the complexity of the problem. A symptomatic patient with HSV-2 clears 
the infection more rapidly during secondary outbreaks, and maternal-fetus transmission rates are 
reduced when HSV-2 specific antibodies are present [4]. Additionally, while co-infection of 
HSV-1 and 2 are not unheard of, the likelihood of acquiring a second HSV infection of the same 
type is much lower once one has already been established [7]. All of this points to the relative 
efficacy of our bodies’ adaptive immune response. Anti-viral drugs like acyclovir also exist that 
suppress viral activity and reduce the symptoms of an outbreak [10, 4].  
The first vaccine candidates tested for HSV-2 were subunit vaccines. These are the 
simplest and safest vaccines to manufacture since they aim to elicit an immune response without 
ever exposing the patient to an HSV-2 particle. Instead, structural/capsid glycoproteins are used 
separately or in combinations with an adjuvant to produce the adaptive immune response 
required. Several combinations of HSV-2 glycoproteins have been tested, and two have made it 
to phase III clinical drug trials. A combination of glycoproteins B2 and D2 (gB2 and gD2 
respectively) with the adjuvant MF59, a proprietary immune response stimulant, was found to 
increase specific neutralizing antibody and lymphoproliferative activity but did not have a 
significant effect on the rate of HSV-2 infection of seronegative test subjects in serodiscordant 
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relationships[18, 4, 106]. A more recent vaccine candidate developed by GlaxoSmithKline is 
composed of truncated recombinant gD2 and an adjuvant mixture of aluminum hydroxide and 3-
deacylated monophosphoryl lipid A [18, 106]. This candidate showed a very promising 70% and 
40% reduction in secondary and primary infections respectively, but only in sero-negative 
women. Unfortunately, these findings could not be repeated in a follow-up study [107]. 
While subunit vaccines have been the only ones to date to reach phase III of clinical 
trials, several other vaccine types have been developed and tested. Peptide based vaccines 
containing T-cell epitopes effective in protecting against HSV-2 have been tested in phase I 
trials. The vaccine HerpV, which consists of a human heat shock protein (Hsc70), an array of 
peptides, and a seronin adjuvant, has recently (2011) shown promising response from CD4
+
 and 
CD8
+
 T cells. This is not only the first HSV-2 vaccine candidate to elicit this kind of response, 
but also the first demonstrated successful use of a human heat shock protein (proteins released by 
human cells under high stress) in a human vaccine [108, 18]. Unfortunately this is the only 
peptide-based vaccine that has shown any kind of efficacy against HSV-2. 
Live virus vaccines have the advantage of eliciting a broad spectrum immune response 
from the body. There are however safety concerns with using any live pathogen as a vaccine. It 
is always a balancing act between making the vaccine safe and having it be effective [109, 18]. 
Attenuation can be achieved in different ways, but the most common method, in recently 
developed vaccine candidates, is deletion of key genes responsible for viral self-replication [18, 
110]. Several candidates have been tested and some are currently involved in clinical trials after 
successfully demonstrating induction of partial immunity to infection or reduction of re-current 
symptoms. Early efforts included HSV-1 virus with a deletion to the gene encoding for ICP27 
(an important gene expression regulatory protein [2, 18]). This gene was replaced with another 
segment encoding for various HSV-2 glycoproteins (gD, gG, gI, and part of gE) making it both 
an attenuated and a subunit vaccine. This effort was abandoned after demonstrating weak 
immunogenicity [48]. Both HSV-1 and HSV-2 with deletions to the gene encoding gH (which 
complexes with gL and is a major factor to infectivity of the virus to host cell membranes [111, 
2, 21]) have been shown to reduce lesions from re-current infections in both guinea pig model 
clinical trials and phase I clinical trials (in the case of the HSV-2 version, called DISC or 
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disabled infectious single cycle)[112, 18]. The HSV-2 version of the DISC vaccine has not 
proceeded to further trials in spite of effective induction of immune response [113]. 
DNA immunization is another method which has been attempted for HSV protection. 
This form of immunization is intrinsically safer than many other methods (especially live virus 
vaccines) due to the presence of only viral DNA. As well, vaccines in this form are inexpensive 
to produce in high doses with very high purity [114]. Delivery of the DNA can be infection free 
if an aqueous solution of attenuated viral vector is used, easing vaccination. Unfortunately, the 
doses required for a detectable immune response are very high compared to other vaccines and 
even then, the T-lymphocyte response was less than anticipated; only 25% of trial participants 
showed a response [18].  
Live virus vaccines are most applicable to this body of work and one very promising example 
still in the pharmaceutical pipeline is ACAM529. This double-deletion virus strain is completely 
unable to replicate unless it is infecting its complementing cell line (AV529-19) thanks to the 
absence of the UL5 and UL29 genes [110]. Both of these genes encode proteins related to gene 
replication and so while the virus is able to infect host cells, cause cell death, and elicit a full 
immune response, it is unable to replicate further. This vaccine has already succeeded in granting 
protection against HSV-2 infection in animal models in pre-clinical research [115].  
2.2 Production of Virus Particles 
Production of virus particles on any scale entails several unique challenges due to the nature of 
the product. The particles cannot self-replicate and so must be produced in a host cell line just 
like any cell product. Unlike cell proteins and other metabolites which may be produced through 
bio-manufacturing, virus particles possess a life-cycle of their own which changes the dynamics 
of the production process. Viral infection titer must be regulated to achieve optimal yield while 
also controlling for cell lysis and extracellular virus stability. In addition, most viruses produced 
are required to be both replication deficient and at a high level of purity given that they are often 
used as vaccines. There are a variety of ways to achieve replication deficiency in the virus 
particles and whatever the method used, the production process must account for it. High purity 
requirements introduce additional costs in down-stream processing which may outweigh the 
benefits of some production methods. Finally, each virus possesses unique properties which can 
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cause issues in production, such as HSV’s tendency to infect cell-to-cell instead of budding into 
the supernatant where it is easier to isolate.  
2.2.1 Cell Culture for HSV Replication 
Cells grown for the express purpose of HSV-2 replication are selected based on several factors. 
HSV-2 is a mammalian pathogen and cannot be replicated in simpler eukaryotic or prokaryotic 
cells. Simpler cells lack the required mechanisms to facilitate viral protein production and gene 
replication. Of the mammalian cell lines available for research and industrial applications 
African Green Monkey Kidney (Vero) cells [116, 117], Chinese Hamster Ovary (CHO) cells 
[29], Human Corneal Fibroblasts [118, 119], and HeLa cells (immortal human cancer cells) [29] 
are the most popular. Other cell lines include Madin Darby Canine Kidney (MDCK) cells, Baby 
Hamster Kidney (BHK) 21 cells, and Chick Embryo Fibroblasts [120]. In 1998 the World Health 
Organization recommended the use of Vero cells for the production of vaccines [121], and the 
majority of work with HSV-2 has been conducted with this cell type. While much of the 
information discussed below will be applicable to all mammalian cell cultures used in virus 
production, the focus is on Vero cell culture and HSV-2 replication. 
Most cells derived from vertebrates are primarily anchorage-dependent cells [122]. This 
means that they replicate only while adhering to an appropriate surface and replicate to form a 
confluent monolayer (a layer one cell thick). When adhered to a surface, the cells’ morphology 
changes and they become much larger along the axes parallel to the surface than they are along 
the perpendicular axis [123]. Some cells continue growing after having completely filled the 
space available with their monolayer which necessitates the cells growing on top of each other 
rather than the artificial substrate [124]. This stratification is highly limited by the lack of an 
extracellular matrix in most cell culture applications outside of tissue engineering [124], which is 
not used in virus production. It is possible, through some modification, to adapt adherent cells to 
growing without any anchorage [125]. This can be useful in certain specialized applications 
There are advantages and disadvantages to both adherent and non-adherent cultures. The 
former makes cells easier to visualize using light microscopy as they grow in a two-dimensional 
manner [122]. This allows for easy monitoring of cell culture growth and health. Being most 
cells’ natural growth pattern, it also removes the need for adaptation to different conditions. The 
main drawback to adherent cultures is the limitation of space in the two dimensions available. 
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Cells growing in suspension remain in contact with media even at very high densities while 
adherent cultures are limited to the available treated surface area [122]. This makes scale-up of a 
production process with anchorage-dependant cells more difficult and requires specialized 
technologies.   
2.2.1.1 Traditional Adherent Cell Culture Scale-up 
Scale-up is a necessity in any bio-manufacturing process. Methods which are efficient and 
effective at lab scale become unwieldy and expensive when the required quantities of product 
increase a hundred-fold or more. Suspension cultures can simply be handled using larger 
bioreactors, though mass and heat transport become more complex. With adherent cultures the 
product output is proportional to the surface area available to the cells and the footprint becomes 
a serious issue as the scale increases. The earliest scale-ups in the 1950’s were done using large 
glass Povitsky flasks [120] and suffered for this very reason.  
The disposable roller bottle (Figure 5) was developed in the 1970’s and quickly became the main 
method for large-scale bio-manufacturing [120]. Cells are grown on a curved surface of a 
cylinder rather than a flat surface. This cylinder is rotated at a rate so that the cells all along its 
circumference remain wetted with media. The bottles come in a wide variety of sizes and scale-
up involves the use of hundreds of such bottles at once. Besides allowing for simpler stacking 
and a better surface area to footprint ratio, the roller bottles also introduced media agitation to 
adherent culture which prevents concentration gradients from forming [120]. As a disposable 
technology, roller bottles also eliminate the need for in-line cleaning. Unfortunately, roller 
bottles are still labour-intensive as each must be seeded and infected individually. While roller 
bottles are no longer the golden standard for bio-manufacturing, they are still used for many of 
the processes which were initially validated for them. Modern set-ups have been optimized in 
terms of surface treatments and shapes. 
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Figure 5: Roller bottle cross-section 
Neatly stackable flat-bottom flasks can fit as many as 40 trays in the same space as a single basic 
flask. These are used extensively for the efficient culturing of cells. These flasks also come with 
valves and ports for attaching media pumps and can therefore be used in semi-continuous 
production processes. While these multi-trays can offer a much higher efficiency than even 
roller-bottles for lab work and small-scale manufacturing, they remain too limiting for the 
highest-volume applications [126]. To reach the same efficiency at larger scales, microscopic 
surfaces are often required. 
2.2.1.2 Micro-carrier Cell Culture 
Micro-carriers (MC) allow the efficiency of a suspension culture to be attained with a cell line 
dependant on anchorage, or at least come much closer than previous technologies allowed. They 
also allow the process to be carried out using stirred-tank bioreactors, some of the best-
understood and most optimized equipment available for work with cell culture [120]. The result 
is a culture which can be easily controlled for culture parameters, can be easily adjusted for cell 
density by changing MC concentration, and for which perfusion is easily accomplished [127]. 
The basic concept is the culturing of adherent cells on microscopic particles which can then be 
suspended in media and cultured in a specially designed bio-reactor. This method is almost as 
old as the roller bottle, with the early development starting in the late 1960s [128], and has 
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undergone extensive development as new materials, coating, and morphologies became 
available.  
Materials used for the main matrix of the carriers vary widely in their stiffness and 
application. Dextran, cellulose, polystyrene, glass, gelatin, and silica are all used in commercially 
available micro-carriers [127]. No matter what material is used, the density is always just above 
1g/mL in order to be easy to suspend in culture media. The overall shape of the particles is 
usually spherical, although cylindrical and hexagonal particles are also used. Sizes range from 
100µm to about 400µm with larger carriers available, although these are technically not on the 
micro scale. More unique morphologies exist within these general shape categories as well. For 
example, macroporous carriers have been developed which can protect the cells from shear stress 
within a bioreactor [129].  
The actual process of culturing cells on micro-carriers is the same as for any suspension 
culture except for a few key differences. Since the cells are not actually in suspension the first 
step is to seed the MC. The methods developed are in many cases proprietary to the 
pharmaceutical company that developed them, but the basic concept is almost always the 
addition of the beads to a gently stirred suspension of cells [130]. The attachment occurs without 
any outside assistance in most cases and the cells spread across the surface of the beads if 
allowed sufficient time to replicate. Bead-to-bead transfer is also possible in some cases, 
allowing all beads to become seeded with smaller inoculums. 
The mode of attachment depends on the micro-carrier used. Some are coated with 
positively charged functional groups (which facilitate up to 90% cell attachment but reduced 
growth) or a collagen-like protein (on which cells grow readily but attachment is less efficient) 
[127]. Once a sufficient density of cells is achieved, the micro-carriers can be used like any other 
suspension to produce virus stock. 
2.2.2 Dextran Sulfate Treatment 
The virus production methodology discussed so far has mostly dealt with the properties and 
requirements of the cell culture used. Once the cells are healthy and available in sufficient 
density, the virus is introduced to the system and it is the properties of the virus which drive the 
process. Multiplicity of infection, batch culture time, and virus collection strategies are all 
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optimized for the virus being produced. One property of the HSV specifically is its limited 
budding into the supernatant. The majority of viable particles infect in a cell-to-cell manner or 
remain membrane-bound on the host cell surface. If only the virus particles in the supernatant 
were collected the overall yield would be unacceptably low even before down-stream processing 
(which always comes at a cost to yield).  
This issue can be addressed by simply lysing the cells to free the virus particles, but this 
causes several issues. First, the virus particles within the cells are not all mature and infectious 
and can be difficult to separate from viable ones. The second issue is that lysis increases the level 
of contamination in the process stream significantly. The regulation-mandated threshold on host 
cell proteins and DNA for vaccine candidates is very low and clearing this contamination would 
not only increase costs but also reduce yield [131]. Chemical treatment of the cells in order to 
elute the virus particles allows lysis to be avoided but requires a good understanding of the 
binding mechanisms of the virus particles to the cell membranes. As long as the chemical can 
then be removed from the production stream, elution is the optimal solution. 
Early on in HSV-2 research it was observed that the polyanionic polysaccharide heparin 
had an inhibitory effect on the virus at high concentrations (10-20 mµg/mL) [132]. It was found 
to prevent the infection of cells at the very earliest stages, likely interfering with adhesion to the 
membrane or entry (at the time, researchers could not determine which). Later on it was 
discovered that this property is shared by other sulfated polysaccharides including Dextran 
Sulfate (DS) and chondroitin sulfate [133, 134]. Only a few viruses aside from HSV are inhibited 
in this way and all of these are enveloped viruses. These include cytomegalovirus, vesicular 
stomatits virus, and human immunodeficiency virus [133]. More interesting still was the 
observation that at lower concentrations the polysaccharides actually have the opposite effect 
with some viruses, increasing the infectivity of the viruses [135]. All of this evidence points to an 
interaction between sulfated polysaccharides and the membrane glycoproteins of the virus. 
As discussed in detail in Section 2.1.2.2.1 Fusion and Entry section, viral adhesion to host 
cell membranes occurs through interaction of viral glycoproteins with various cell membrane 
receptors. The very first step of the adhesion process involves glycoprotein C interacting with 
“highly sulfated cell surface glycoaminoglycans, such as Heparin Sulfate” [135]. Both HSV-1 
and HSV-2 bind to these receptors, and although both have alternative routes of entry, their 
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infectivity is severely impacted if a receptor of this type is unavailable [136]. Those virus 
particles which have yet to undergo further adhesion to the host cell membrane can be eluted 
back into solution with the addition of heparin or Dextran Sulfate (DS) [137] and this has been 
found to also be true for membrane-associated progeny virus particles [117].  
Based on the evidence presented above, it has been deduced that a polysaccharide like 
DS can be used to recover membrane-associated virus particles from host cells through 
preferential binding. The reversible nature of this bonding eases purification of the virus particles 
in down-stream processing and since the method is non-disruptive to the cell membrane, there is 
no additional contamination of the product stream. Treatment with DS is used for the HSV-
2/Vero cell vaccine candidate elution at Sanofi Pasteur on a large scale and the purification 
scheme which is made possible by the harvesting method yields a ~200 times more pure final 
product (in terms of host cell contaminants) [110].  
2.2.3 Downstream Processing (DSP) 
Once virus particles have been harvested from the cell culture, they are purified in order to 
remove contaminants. Contaminants can include host cell DNA and proteins, cell media and its 
components, and chemicals added to the product stream (like DS used in cell elution). The 
volume of the process stream is almost always reduced drastically as part of the down-stream 
processing, which concentrates the virus to the concentrations required for the particular 
application. Virus particles, and HSV in particular, are known to degrade and become non-viable 
fairly quickly so stabilizing agents are added [138]. Ultimately, this work should yield insights 
on how to process and recover HSV-2 from Vero cells. Although the downstream processing of 
HSV-2 is not within the scope of this work, a review of DSP of viruses and virus-like particles 
was conducted and is presented in Chapter 3 in order to round out the discussion of this work.
26 
 
Chapter 3 – Downstream Processing of 
Virus Particles from Cell Culture 
This chapter was originally written as a mini-review for a grant application with the help of 
other members of my research group. I would like to acknowledge Megan Logan, Steve George, 
and Stanislav Sokolenko who co-authored the original document, much of which was retained in 
this version. I was first author on the original document and am solely responsible for the work 
which was required to convert it from a 7-page mini-review to its current version for my thesis. 
3.1 Outline 
Virus particles are being manufactured in higher amounts than at any other time in human 
history. The demand stems from research into novel uses for these particles, from both large-
scale and small-scale manufacturing of pharmaceutical products, and from numerous trials of 
novel therapeutic candidates. All require high yields of correctly assembled, and often ultra-pure, 
virus stock. The crude product stream (either lysate or supernatant) must undergo extensive 
down-stream processing (DSP) in order to meet purity regulations in a financially viable manner. 
Making up as much as 80% of overall per-dose cost, DSP represents a significant area for 
optimization and a very active field of research. 
The entire process can be broken down into three main stages. The process starts with 
clarification, which aims to remove large-scale contaminants while maintaining the integrity of 
the desired product. Clarification is being done mostly by disposable filtration units including 
dead-end depth filtration and body-feed filtration. These allow for high throughput while 
minimizing the need for process validation. Aqueous two-phase systems are also being 
implemented, thereby combining clarification with the next step in DSP of virus particles, 
concentration and purification.  
Concentration refers to the reduction of the process volume. Diafiltration can achieve this 
while also removing impurities from the process stream. Membrane technology has become 
more popular than resin chromatography in some applications. Where chromatography is still the 
method of choice, larger pore-size resins are being developed to purify larger molecular-weight 
biological products like virus particles. Monolith columns have also seen a rise in development 
recently. 
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The final stage of DSP is polishing, where the product is brought into compliance on 
purity without sacrificing yield. For this stage, chromatography remains the method of choice 
with research focused on development of more ideal stationary phases. Ion exchange, size 
exclusion, and metal affinity chromatography are currently in use. Diafiltration has also been 
shown to have potential, but may not be appropriate for all polishing applications. 
DSP of virus particles is a field that is very much growing, and ongoing research is 
focused on making the production of high yield and purity particles more cost effective. Novel 
therapeutics and vaccines each come with their own set of DSP requirements and characteristics, 
meaning the field is unlikely to ever reach a point of stagnation and regular reviews of the 
methodology will continue to be required.  
3.2 Introduction 
The production of complex biological particles for use in vaccines and therapeutics is both 
technically difficult and financially restrictive. Any biopharmaceutical manufacturing process 
aims to produce at the lowest possible cost per dose while maintaining the highest standards for 
purity (in terms of host cell DNA, host cell proteins, and presence of chemical reagents [131]). 
This balance is even more difficult to achieve for the newest wave of vaccine candidates and 
therapeutics comprised of large complex biological compounds produced in cell cultures. 
Products like virus-like particles (VLPs), viral vectors, monoclonal antibodies, and various 
nucleotides all show tremendous potential, but come with inherent challenges for DSP. Since 
DSP commonly accounts for as much as 80% of the overall cost of vaccine production [139, 
140], it is a prime candidate for optimization and the development of novel technologies. This 
review focuses on recent developments in the downstream processing of viruses. 
Live viruses can be used to deliver genes of interest into a cell, thereby adding to the 
cell’s genomic content, or resulting in the production of a desired cell product. When used in this 
way a virus is referred to as a viral vector. Viruses may also be produced in a less modified form 
for use in vaccines and for research purposes. Viruses are large for biopharmaceutical products 
(on the scale of 10
7
 Da compared to monoclonal antibodies with a size on the order of 10
5
 [131]), 
which has a significant effect on the DSP. Viruses can be enveloped (structural proteins are 
enclosed in a membrane layer of lipids and glycoproteins [2]) or non-enveloped and may be 
secreted or localize within the cells in which they were produced. In most cases, enveloped 
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viruses are found on the outside of the cell as they acquire their envelopes as part of a secretory 
pathway with membrane proteins trafficking to the plasma membrane [141, 142].   
Challenges to DSP arise based on the nature of the virus production process. Enveloped 
virus particles may not require cell lysis for separation, but they can also be sensitive to shear 
stress and osmotic pressure due to the labile nature of the envelope [143]. When production of 
virus particles occurs in bacterial cells, endotoxins become a major concern and must be 
eliminated quickly to ensure protein stability [144, 145]. In insect cell systems, baculovirus may 
be co-produced and have a molecular weight similar to that of the desired product [146]. Other 
systems may be required to produce highly variable products, such as those producing different 
influenza vaccines every year to keep up with natural mutations [147]. It is clear that the 
processing of virus particles must be not only high resolution but also specifically tailored to the 
system in question. 
DSP of virus particles can be broken down into three stages: clarification, concentration, 
and polishing (Figure 6). The advances in each area are covered separately below for a wide 
array of applications. The actual process steps used depend in large part on the properties of the 
product and process stream. As with any separation process, reduction of stream volume is done 
as early as possible to minimize overall costs and reduce the required equipment size. 
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3.3 Clarification 
Every virus particle production process begins with upstream production in a cell culture. Once 
this step is complete, a preprocessing step may be necessary before clarification can begin; the 
virus particles must be separated from the host cell so they are released into the cell media. Cell 
lysis may be needed in case of intracellular products such as non-enveloped viruses e.g. 
adenoviruses [148, 149]. Additives can also be mixed with the starting solution to help with the 
freeing of virus particles from the cellular membranes, as with the case of HSV-2 where Dextran 
Sulfate is used to help dissociate the virus from the cell membrane [150]. 
Extracellular products have the benefit of being excreted from the cell and can be isolated 
in the supernatant without extra processing steps [151] and cell lines are even being genetically 
engineered to efficiently excrete the virus particle to aid in the downstream processing [131]. 
Protease inhibitors are another additive added at this stage in order to protect the final product 
from degradation[152, 153]. Those systems in which cell lysis is unavoidable almost invariably 
suffer from higher host cell protease concentrations. In general, while adding extra components 
may aid in the initial separation process, these compounds have to be removed in subsequent 
purification steps. This can add further complexity to the purification and polishing steps and the 
overall yield can suffer for it. 
Figure 6: Summary of DSP of virus particles 
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Flocculation can be used as a pre-clarification step to aid in the separation of cellular 
debris from the product. It involves the addition of other components such as inorganic salts, 
organic solvents, acids or bases to the cell media to precipitate out unwanted contaminants or to 
precipitate the product [149]. This has primarily been used for intracellular VLP’s [154]. This 
step is usually followed by centrifugation of the flocculated material. 
Clarification is the first major step in the downstream bioprocessing of a cell culture fluid 
solution. The main goals of this step are to remove cells, cell debris and other large contaminants 
and to condition the fluid for further downstream processing. Clarification usually follows a 
general 3-step process: centrifugation to remove cells and solid, depth filtration to remove 
smaller particles, colloids, and contaminants and a final filtration step to reduce the amount of 
biological material further. This is done to avoid filter or column clogging in later purification 
steps [155]. 
The mechanical separation of large particulates has traditionally been done by 
centrifugation. However, with the rise of single-use, disposable units for biomanufacturing 
centrifugation is in some cases replaced with a series of dead-end depth filters with diminishing 
pore size [131, 156]. Pore sizes start out fairly large (~3µm) and then decrease to about 0.45-
0.8µm [157, 158]. Single use filters reduce the need for cleaning and validation, decreases the 
change-over time, and lowers the risk for cross-contamination in multi-purpose facilities [159, 
160, 161]. Along with these benefits depth filtration has limitations such as filter blocking, 
turbidity breakthrough (the piercing of the membrane by contaminants due to the buildup of 
pressure), and required pre-flushing of the filter material [155]. For these reasons research has 
been directed at searching for alternative single-use methods for clarification: cross-flow 
filtration and body-feed filtration [162, 163, 164, 131, 165]. 
Cross-flow filtration is done by pumping the feed in a tangential direction across the 
membrane while having pressure applied to the system to allow the permeate to pass through the 
membrane. Particles that are too large to pass through the membrane remain in the retentate and 
are recirculated [164]. The principle of using cross-flow filtration is to avoid clogging of the 
membrane. There are different membrane configurations, such as hollow fiber, flat sheet, 
tubular, spiral wound and vibrating membrane systems and each has their own advantages and 
disadvantages [166]. Even though these methods can handle high solids loads, they can result in 
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poor yields due to polarization at the membrane surface and sometimes require excessive 
dilution of the product which can limit the use of this technology [149]. 
Body-feed filtration has been adapted from the plasma fractionation industry and it was 
originally used to fractionate human plasma into its components such as albumin, clotting factors 
and immunoglobulins [167, 168, 169]. It uses selective precipitation by adjusting pH, ionic 
strength, addition of alcohol and temperature changes to form precipitates that are then removed 
by depth filtration. It involves a two step process; 1) adding a precoat of the filter aid (for 
example diatomaceous earth or cellulose fiber) to the filter septum and then 2) continuously 
adding small amounts of the filter aid to the liquid so that a new filtering surface is continuously 
being added (Figure 4) [170]. The disadvantage of this technology is that by the addition of filter 
aids, there is an increased risk of product contamination and cross-flow membrane fouling, 
which would reduce the flux rates [154].         
 
Figure 7: Comparison of dynamic body-feeding filtration and traditional depth filtration (image adapted from van der Meer 
et al. 2014) 
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One recent trend aimed at reducing DSP costs is the combination of clarification with 
concentration and purification. Some ways of accomplishing this are by doing a direct capture of 
the product with an expanded bed adsorber, by using a multi-stage aqueous two-phase extraction 
[166, 171], or by using disposable cross-flow filtration systems [165]. Expanded bed adsorption 
works like classical chromatography, but the solid resins are in a fluidized state which creates 
larger voids for whole cells, or cellular debris to pass through. In practice there is interaction 
between the biomass and the adsorbent phase, which causes increased buffer consumption and 
decreased sorption performance [172].  
Aqueous two-phase systems (ATPS) are composed of either water soluble polymers 
(such as polyethylene glycol or dextrin) or a combination of a polymer and a salt [173] in a 
system composed mostly of water (making for a relatively bio-particle friendly environment) 
[174]. The process works by having the two phases separate the proteins/virus particles based on 
their surface properties. This has been successfully used for purification of many biological 
products including organelles, bio-nanoparticles, and genetic material [175, 176]. This method is 
easy to scale-up, can be low-cost (especially from the materials cost side), and has the ability to 
select particulate materials from the crude cell media [177]. There are still many disadvantages 
to this method due to its novelty (as a large-scale manufacturing DSP method) including large 
amounts of process development required, low capacities and limited mechanistic understanding 
[177].  
Where implemented, ATPS has been found to carry the risks of loss in virus infectivity 
(in viruses sensitive to high ionic strength solutions), protein co-purification, and difficulty in 
recovering polymers [178]. On the other hand, most non-enveloped viruses can maintain 
infectivity under these conditions. It has already been demonstrated that ADPS can be used as a 
combined clarification-purification step for porcine parvovirus, achieving a high infectious yield 
and separating major contaminating proteins effectively [178]. Adenovirus [179], Adeno-
associated virus[173], Poliovirus [180], and Malignant Catarrhal Fever Virus [181] have all been 
successfully purified with ATPS.   
3.4 Concentration and Purification 
The goals of this stage of DSP are to reduce the process volume as much as possible and to 
remove host cell proteins (HCP), host cell DNA (HC DNA), and other impurities such as lysis 
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reagents used to disrupt cells. While ultracentrifugation is the most established technology for 
this kind of processing, membrane and resin chromatography based systems have seen increased 
popularity due to the easy scale-up as well as advantages in selectivity and footprint.  As a first 
step though, diafiltration is a useful method to remove small molecule impurities like detergents 
[182], to exchange buffers [183], and to concentrate the process stream.  
Various modes of operation are possible, with constant volume diafiltration reported to 
give VLP recovery yields of about 78% with murine polyomavirus VLPs [183]. A further 
concern is the need for the removal of HC DNA to comply with federal regulations. This is 
currently done using the addition of benzonase to a concentrated stream prior to further 
purification, and can be integrated into a discontinuous diafiltration process, such that benzonase 
can then be removed during the buffer exchange step [184]. 
A major concern for filtration steps is the need to establish process parameters that would 
reduce membrane fouling, while providing acceptable concentration factors. For instance, a 
higher operating pressure and flow rate would increase the amount of liquid processed per unit 
time, and may provide higher concentration factors, but can cause membrane fouling [182, 183]. 
Diafiltration can be run in tangential flow modes to reduce this problem [185]. This process has 
been shown to remove up to 90% of the host cell proteins and DNA from a rotavirus VLP 
process stream [182]. 
The most common next step of the process involves the purification and concentration of 
the product of interest using “positive chromatography” in the bind-elute mode [131]. These 
processes can be classified into ion exchange chromatography, affinity chromatography, 
hydrophobic interaction chromatography, and size exclusion chromatography [186], with the 
type of purification strategy being used depending on virus characteristics such as size and 
surface charge.  
Recently, some interest has grown in using biomimetic design for the development of 
new affinity chromatography ligands. By using binding structures from known receptor proteins, 
it has been shown that very high affinity can be achieved for specific proteins of a VLP. Such a 
custom ligand was developed for a VLP of murine polyomavirus (MPV) by Yanying Li and his 
group in 2014. This ligand was shown to be efficient enough to purify the VLP capsomeres from 
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crude cell lysate in a single separation step, followed by successful self-assembly of the particles 
[187]. While this approach shows great promise in challenging separation environments, using 
biological systems for the production of affinity ligands is expensive, time-consuming, and 
reduces their applicability for scaled-up manufacturing processes. Luckily, the fields of 
molecular modeling and combinatorial chemistry are growing quickly and can provide more 
cost-effective ligands without any threat of contamination for VLP and virus purification [188]. 
Traditional chromatography, using beads and absorptive resins as supports, depends on 
the transport of the product of interest into pores which are usually quite small, usually 60 - 100 
nm [189]. In addition, high shearing forces can be present within the column [190]. This is 
difficult for bulky virus particles and these processes must be run at low flow rates [171]. In 
addition, fragile enveloped virus particles, and filamentous viruses can be especially sensitive to 
shear forces, and their purification by resin bead chromatography may be problematic.  Large 
pore size membrane adsorbers are an excellent solution to these problems, and can be operated at 
higher processing rates. They also allow for lower pressure drops [191] and higher flowrates that 
can reduce process times up to 10% compared to traditional columns [192].  Monolithic 
columns, which are highly porous and contain uninterrupted and interconnected channels, offer 
the advantages of membranes, such as large pore size of up to 1500 nm [193], but with increased 
resolution, and lower dead volume [186]. Monoliths are more common in polishing and are 
discussed in more detail below. 
There are many examples of column resin-based separation processes for the purification 
of virus particles [186]. Membrane technology, however, is relatively new, and the two most 
popular membrane devices are the Mustang
®
 and Sartobind
®
 resins from Pall and Sartorious 
respectively. Scale-up compatibility with this technology is also excellent, allowing for 
processing capacity of up to 100kg [194]. Ion exchange membranes have been used for the 
purification of AAV [195], Adenovirus [185], Baculovirus [196, 197], Lentivirus vectors [198, 
199, 200], Retrovirus vectors [200] and Influenza vaccines [201].  
Various affinity membranes have been used for virus purification, including the use of 
sulfated heparin membranes for the purification of vaccinia virus [202, 203] and influenza virus 
[204], and metal affinity resins for the purification of influenza virus [205] and adenovirus 
vectors [206]. 
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The purification of biologics by monolith columns is even newer than that by 
membranes, and there is now much interest in their use for virus particle purification. These 
columns have been shown to be much superior to traditional resin bead columns in terms of virus 
particle recovery, and ease of operation, which stems from their open pore structure which 
provides increased accessibility to the interior [207]. Monolith columns also offer non-turbulent 
flow and low pressure drops even at high flow rates [190]. Ion-exchange monoliths have been 
used for the purification of bacteriophage [208], baculoviruses [209], enterovirus 71 [189], 
influenza viruses [210], tomato mosaic virus [193], and rubella virus [190], and for the 
purification of adenovirus VLPs [211]. In addition, hydrophobic interaction chromatography 
using monoliths has been used for the purification of Hepatitis B VLPs [207]. Affinity 
chromatography in monoliths has also been done for the purification of lentiviral vectors by 
metal ion affinity columns [212] and biotinylated retroviral vectors by strepavidin functionalized 
monoliths [213].  
Monolithic column chromatography methods often report very high recoveries, especially 
when compared to traditional bead chromatography. Monolith columns have also been 
successfully used for the purification of filamentous viruses, albeit with lower recoveries of 
about 50% [208]. Other types of chromatography have also been used for virus purification 
including hydrophobic interaction chromatography [202] and hydroxyapatite pseuodoaffinity 
chromatography [214]. A detailed review of chromatography-based virus purification strategies 
used for different viruses prior to 2010 can be found elsewhere [186]. 
3.5 Polishing 
Polishing represents the final step in downstream processing. What that entails depends in large 
part on the global processing scheme and virus. However, clinical grade material will typically 
have stringent requirements on contaminating DNA or protein content as function of dose 
amount [215]. As the input material has already undergone one or more processing steps, 
polishing can involve more specialized approaches, tailored to the requirements of the overall 
process. Furthermore, a previous reduction in contaminating material and concentration 
facilitates applications that would be too costly to apply to crude cell supernatant or lysate. These 
factors combine to make chromatography one of the only practical polishing options [131, 215, 
216] 
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Despite the strong focus on a single methodology, new polishing options are emerging 
with developments in chromatography technology. The biggest of these have been in the use of 
different stationary phases. The typical approach of using bead resin has significant issues with 
poor diffusion of large biomolecules such as VLPs and viruses due to small pore size and high 
pressure requirements.  Decreasing bead size for improved diffusion only exacerbates the issue 
of pressure [217]. The result is a tradeoff between processing time and possible damage to highly 
sensitive membrane glycoproteins [216].  One solution to this problem has been to move to 
single-piece “monolith” or membrane stationary phases [217]. As previously mentioned, both 
feature much larger channels that allow greater access for large biomolecules. A recent monolith 
application has reported improved flow rate as well as capacity [207], with other reports of good 
DNA clearance [218]. In another case, an overall process yield of 38-45% was achieved for 
canine Adenovirus polished with anion exchange monoliths [219]. Apart from changes to the 
stationary phase, different chromatography configurations are also being explored [220]. 
Of the various available chromatographic techniques, two are commonly encountered in 
polishing applications. General polishing makes use of size exclusion chromatography to filter 
out small contaminating particles such as DNA or proteins. However, new developments in ultra 
and diafiltration make them competitive options in some applications [143]. While there are 
reports of using only diafiltration as the final processing step [221], it is difficult to generalize 
such reports to all polishing needs. For more specific applications, ion exchange and affinity 
chromatography remain the preferred options [215]. While ion exchange may not be enough to 
discriminate between two different virus capsids, there have been new developments in the use 
of various fusion tags such as polyionic  insertions [222]. The insertion of a polyionic tag has 
been demonstrated for a polyome VLP, albeit not in the context of chromatography [223].  
There has also been at least one case of using immobilized metal affinity chromatography 
for VLP separation, without the need for a His-tag [224]. The researchers argued that the natural 
occurrence of histidine and other protonated amino acids (such as glutamic and aspartic acid) 
was enough for electrostatic interaction with the metal-ion-matrix. While affinity 
chromatography offers the greatest sensitivity of all the polishing methods, elution can remain a 
challenge due to capsid sensitivity [215]. 
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3.6 Conclusion 
Downstream processing of virus particles is a fast-growing field of research in which well 
entrenched traditional separation methods are currently competing against emerging 
technologies. Traditional approaches have a higher breadth of research available into their 
implementation and more work has been done on their optimization. In many cases, the older 
technologies are in higher supply and can perform much the same tasks at a lower cost. On the 
other hand, newer methods offer many advantages including higher resolution of separation, 
lower diffusion mass resistance, and disposable units (no cleaning or validation required).   
Many challenges and opportunities for research breakthroughs remain for the field of 
virus particle DSP. Separation of similar and/or closely related viral species with similar physical 
and chemical properties remains difficult. Depending on the application, viral activity is either a 
requirement or to be avoided resulting in process-specific challenges not easily solved. Viral 
inactivation during DSP is still not well understood in many cases [225]. Aggregation of viruses 
and viral proteins is an issue in almost every DSP technology and results in loss of overall yield 
of usable product if not carefully controlled [226, 225].  
As with any manufacturing process the overall cost-effectiveness is a very important 
deciding factor. The lowest cost per dose possible while meeting all regulatory requirements for 
purity is the ultimate goal of many DSP schemes. Whether this means returning to the “golden 
standard” or investing in the state of the art depends on the product and the preference of the 
engineers designing the system. 
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Chapter 4 – Materials and Methods 
4.1 Cell lines and virus stock 
4.1.1 Vero cell culture maintenance and methods 
Unless otherwise noted, all experiments described were conducted using a genetically modified 
HSV-2 strain and complementing cell line in which it is able to replicate. The virus, ACAM529, 
is deficient in two genes. The first, UL29, codes for ICP8, which is required for binding of viral 
DNA and DNA synthesis. The second, UL5, encodes a “component of a heterotrimeric helicase-
primase complex”[2] that interacts with ICP8. Therefore, this virus cannot replicate in regular 
human cells. As a result ACAM529 has a reduced biohazard risk designation of Risk Group 1 
(wild type HSV is designated Risk Group 2). ACAM529 is also referred to as dl5-29 in older 
literature.  
The complementing cells are from a cell line called AV529-19 (also known as HSV2013-121), 
which is a Vero cell line that has been stably transfected with plasmids pCId. UL5 and 
pcDNA.UL29 (Dr. David Knipe, Harvard Medical School). This transfection enables the cells to 
“rescue” the virus and allow it to replicate. A second stable Vero cell line (HSV2012-121), based 
on AV529-19, transfected with another plasmid containing the gene for the enhanced Green 
Fluorescence Protein (eGFP) under the HSV-2 ICP10 promoter, was also used in the body of this 
work. 
4.1.1.1 Vero cell culture maintenance 
Vero cells were cultured in flat-bottom surface tissue culture flasks; either a T150 flask with 
~50cm
2
 surface area (Fisher Scientific, Whitby ON, CA, cat #:12556-011) or a T175 with 
~75cm
2
 (Corning Cellgro, Manassas MA, USA, cat #: 29186-105). Cells were grown in 
Dulbecco’s Modified Eagle Medium (DMEM) with F12 supplement (Corning Cellgro, Manassas 
MA, USA, cat #: 90-090-PB), 4mM L-Glutamine (Fisher BioReagents, Loughborough, UK, cat 
#: BP379-100), and 10% Fetal Bovine Serum (Gibco Life Technologies, Burlington CA, SKU #: 
12483-020). Initially, cultures were provided with 1mM Puromycin (Corning Cellgro, Manassas 
MA, USA, cat #: 61-385-RA) and 1% G418 Sulfate (Corning Cellgro, Manassas MA, USA, cat 
#: 30-234-CR) but both of these antibiotics were removed from the media for the majority of the 
work to reduce stress on the cells.  
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Cells were seeded in the culture flasks at between 1.0x10
5
 and 1.5x10
5
 cells/mL and 
allowed to grow to confluence (monolayer of cells completely covering the surface of the flask). 
Confluence was monitored visually using an inverted light microscope. To passage cells, media 
was aspirated and the cells washed using Dulbecco’s Phosphate Buffered Saline (DPBS) (Life 
Technologies Inc., Burlington ON, Canada, cat #: 14190-144). Once washed, the cells were 
treated with TrypLE Select enzyme (Life Technologies Inc., Burlington ON, Canada, cat #: 
12563-029) for 10 min to dislodge the cells from the culture flask surface. The cells were 
resuspended in media (containing FBS as described above) for aspiration (volume dependent on 
the flask size) which also deactivated the TrypLE thanks to protease inhibitors contained in the 
FBS [227]. The suspended culture was then centrifuged at 115 x g for 5min and the supernatant 
containing TrypLE was removed. Lastly, the cell pellet was resuspended in fresh media and the 
cells seeded into a new flask. 
4.1.1.2 Cell banking 
A cell bank was created by freezing cells in liquid nitrogen (-196 ºC). First, cells were grown to 
confluence in one or more T175 T-flasks. Cells were then recovered using TrypLE centrifuging 
at 115 x g for 5 min and resuspend the cells in a solution of cell media and 10% DMSO (Sigma-
Aldrich, Oakville ON, CA, cat #: D2650) at 1.0-5.0x10
6
 cells/mL and aliquoted into 1mL 
cryogenic vials (Thermo Scientific Nalgene, cat #: 5000-0020). The cryovials were then placed 
directly into liquid nitrogen for storage. The cell banks were maintained at around -196 
o
C in 
liquid nitrogen within a double-insulated Dewar flask once frozen. 
4.1.1.3 Thawing cells 
Thawing of the cells was conducted whenever a new culture was required. It was also done right 
after a batch of cells was banked to ensure freezing was conducted effectively and frozen cells 
were viable. To thaw out cells, one cryo vial was removed from the liquid nitrogen Dewar flask 
and placed in a 37 
o
C water bath. Once thawed, the cells were pipetted drop by drop into 
DMEM/F12 cell media. The suspension was then centrifuged at 1000rpm for 5min and the 
media aspirated to remove the DMSO. Lastly the cells were resuspended in fresh media and the 
whole suspension was used to seed a T150 culture flask. 24 hrs after seeding the thawed cells, 
the cell media was replaced to remove dead cells and any remaining DMSO. Post-thawing, the 
Vero cells were passaged at least twice before they recovered from their freezing and could be 
used in experiments. 
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4.1.1.4 6-Well plate cultures for transcript analysis 
A 6-well plate was seeded at 2x10
5
 cell/mL, two wells with AV529-19 and four with HSV2012-
121, and incubated overnight. A confluent monolayer was not required for this investigation 
given that the results were entirely qualitative and the infection compromised confluence 
regardless of initial cell density. The two wells containing HSV2012-121 had their media 
aspirated and diluted viral stock added for 1 hr. After replacing infection media with fresh media 
all wells were incubated for an additional 18 hrs to allow infection to progress.  
4.1.1.5 Culture of Vero cells in the presence of sodium butyrate (NaBu) 
4.1.1.5.1 Uninfected controls and protocol optimization 
6-well culture plates were seeded with HSV2012-121 Vero cells at 1.5x10
5
 cells/mL. NaBu was 
either added immediately after seeding at 0, 1, 2, 3, 4 and 5 mM, or 24hrs after seeding, at 0, 1, 
2, 3, 4 and 5 mM. At 48 and 72 hours after seeding, both plates were imaged with fluorescence 
and light microscopy. Light images were taken at 40x magnification to capture as much of the 
culture as possible while fluorescence images were taken at 100x magnification. The higher 
magnification allowed the images to focus on the more fluorescent sections of the culture. The 
images were analysed in a qualitative manner to determine the level of cell death and eGFP 
leakage. Cell death was easily discerned in the culture as dead cells become rounded and 
detached from the culture plate surface. eGFP levels were described by comparing them to the 
control well fluorescence.  
4.1.1.5.2 Infecting cultures under optimal NaBu addition protocol 
A 6-well plate was seeded with HSV2012-121 Vero cells at 1.5x10
5
 and spiked with NaBu at the 
time of seeding. NaBu concentrations of 2mM and 4mM was used. At 24hrs after seeding, the 
plate was infected with ACAM529. The viral infection medium contained no NaBu and was 
replaced with fresh DMEM media with NaBu at the proper concentrations after 1 hour was 
allowed for viral attachment to the cells.  
4.1.1.6 96-well plate culture and infection of Vero cells 
A 96-well culture plate was seeded with 100µL of HSV2012-121 cells at 2.5x10
5
 cells/mL and 
allowed 18-24hrs to attach at 37
o
C and 5% CO2. Of the 12 wells in each row of the 96-well plate, 
10 were seeded with cells, while the 2 wells at the edges of the plate were filled with 150 µL of 
water. Similarly, the two rows of wells along each of the long sides of the 96-well plate were 
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also filled with water. This was done to reduce the effect of evaporation. Infection and EPDA 
quantification were conducted as per Section 4.3. 
4.1.2 Insect cell system 
4.1.2.1 Sf9 cell maintenance 
Sf9 cells (ThermoFisher Scientific, Cat.# 12659-017) were cultured in 125 mL shake flasks 
(Pyrex Glasswear, Corning, NY, #4985) in an incubator at 27 
o
C using Sf900 III serum-free 
media (Gibco Life Technologies, Burlington, CA, Cat.# 12658019). Each flask was maintained 
at between 1x10
4
 and 5x10
6
 cells/mL and any culture below a viability of 95% was replaced with 
a fresh batch of cells. For this investigation, a clear-bottom 96-well plate was seeded and 
infected.  
4.1.2.2 Baculovirus Stock 
The baculovirus construct used in the experiments presented in this thesis was created in our 
laboratory by my colleague Steve George. The GFP gene was isolated from the pcDNA3-GFP 
plasmid (Addgene, Cambridge, MA, Cat.# 13031) and was then cloned into Autographa 
californica multicapsid nucleopolyhedrovirus (AcMNPV) (BD Pharmingen, San Diego, CA) 
using overlap extension PCR. The full protocol is described in Steve’s published work [228]. 
Viral stocks were kept at -80 
o
C and thawed before each experiment in the 27 
o
C water bath. 
4.1.2.3 96-well plate culture and infection of Sf9 cells 
The Sf9 insect cells were known for occasionally clumping and showing other signs of non-
exponential growth so a clear-bottom plate was used to confirm that they still formed a uniform 
attached layer in the wells. For infection, 100µL of a 5x10
5
 cells/mL Sf9 culture suspension was 
distributed to each well of the plate. The plate was incubated overnight (18-24hrs) to allow for 
cell attachment. 96-well plates were always incubated within a BioTransport Carrier (Thermo 
Scientific Nalgene, cat #: 7135-0001) which maintained high humidity in order to minimize 
evaporation. Baculovirus stock (maintained as per Section 4.1.2.2) was then diluted and added to 
the wells for infection. The dilution was done serially as per Section 4.3. The wells in each row 
of the 96-well plate were infected with 10µL of the same dilution (12 replicates for each of the 
dilutions). The plates were then incubated to allow the infection to proceed before the EPDA 
quantification could proceed (Section 4.3). 
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4.2 Cell counting  
Cells were diluted using a 0.5%  V/V solution of Trypan Blue in DPBS (HiMedia Laboratories, 
Mumbai, India, cat #: TCL005) and counted using a Hemocytometer (Hausser Scientific Co., 
Horsham PA, USA, cat #: 3720).  
4.3 Plaque assay 
12-well tissue culture plates (Thermo Scientific Biolite, Korea, cat #: 130185) were seeded with 
AV529-19 Vero cells at 2.5x10
5
 cells/mL (1mL per well) and incubated overnight to achieve 
confluence. Once cells were confluent, the media was aspirated and the cells washed once with 
DPBS prior to infection. Virus stock was serially diluted from its original concentration and 200 
µL of each dilution was used to infect 3 wells. The cells and infection media were incubated for 
1 hr at 37 
o
C and gently rocked every 15min to ensure even viral attachment. After 1hr the 
infection media was replaced with overlay media (DMEM culture media + 7.5% methyl 
cellulose (Sigma Aldrich, St. Louis MO, USA, cat #: 274429)).  
The culture plates were incubated for 48 hours to allow plaques to form. The overlay media was 
removed and the plates were stained with 1% crystal violet solution in methanol (Sigma-Aldrich, 
St. Louis MO, USA, cat #: HT90132) for at least 30min. Plaques were counted after washing off 
the crystal violet solution and dried, yielding a  titer in “plaque forming units” (PFU)/mL. Taking 
into account dilution, and using triplicates to establish reasonable statistical confidence, the 
initial infectious virus titer is given by: 
Equation 1: 𝑽𝒊𝒓𝒖𝒔 𝒕𝒊𝒕𝒆𝒓 (
𝒑𝒇𝒖
𝒎𝑳
) =
𝑨𝒗𝒆𝒓𝒂𝒈𝒆(𝒑𝒍𝒂𝒒𝒖𝒆𝒔)×𝑫𝒊𝒍𝒖𝒕𝒊𝒐𝒏
𝑽𝒐𝒍𝒖𝒎𝒆 𝒐𝒇 𝒗𝒊𝒓𝒖𝒔 𝒔𝒐𝒍𝒖𝒕𝒊𝒐𝒏 𝒂𝒅𝒅𝒆𝒅
 
4.4 End point dilution assay (EPDA) 
HSV2012-121 cells were seeded at 2.5x10
5
 cells/mL in a clear-bottom 96-well plate (Corning 
Costa, New York NY, USA, cat #:3603) and incubated overnight to achieve confluence. The 
virus stock was serially diluted with media up to a factor of 10
9
. Plates were incubated for 24-
48hrs to allow infection to progress and fluorescent protein to be produced. Each well was scored 
based on the presence of infection (fluorescence above baseline).  
First, the cumulative positively and negatively scored wells at each dilution level were 
calculated. Infected wells were counted starting from the highest dilution while uninfected wells 
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were counted from the lowest dilution. The cumulative number at each dilution level was 
recorded and these values were then used to find the percentage of wells infected overall at each 
dilution. The “tissue culture infective dose” (TCID50), which corresponds to the virus dose that 
causes 50% of the cultures to be infected, was calculated according to Equation 2. 
Equation 2: 𝐥𝐨𝐠(𝑻𝑪𝑰𝑫𝟓𝟎) = 𝐥𝐨𝐠(𝑫𝒊𝒍𝒖𝒕𝒊𝒐𝒏>50% 𝑖𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛 ) − 𝑷𝑫𝒓𝒆𝒔𝒑𝒐𝒏𝒔𝒆 
where PDresponse is the proportional distance of the dilution giving greater than 50% infection to 
the dilution factor which corresponds to the TCID50. 
Equation 3: 𝑷𝑫𝒓𝒆𝒔𝒑𝒐𝒏𝒔𝒆 =
(𝑷𝒆𝒓𝒄𝒆𝒏𝒕>50% 𝑣𝑎𝑙𝑢𝑒−𝟓𝟎%)
(𝑷𝒆𝒓𝒄𝒆𝒏𝒕>50% 𝑣𝑎𝑙𝑢𝑒−𝑷𝒆𝒓𝒄𝒆𝒏𝒕<50% 𝑉𝑎𝑙𝑢𝑒 )
 
Multiplying the TCID50/mL by 0.69 yields the plaque-forming units per mL (PFU/mL). 
4.5 Spectrofluorometric analysis  
EPDAs and other investigations involving the spectrofluorometer were conducted using black-
bottom (Thermo Scientific Nunclon, Roskilde Denmark, Cat. # 137101) or clear-bottom 
(Corning Costar, Corning, NY, USA, #3603) 96-well plates. Most of the work was done using 
the clear-bottom plates which allowed visual tracking of the progress of infection. The 
spectrofluorometer was a BioTek Synergy 4 plate reader (BioTek, Winooski, VT, USA).  
Before each 96-well plate was examined using the fluorescence plate reader (another 
name for the spectrofluorometer), the lid was removed and replaced with MicroAmp optical 
adhesive tape (Applied Biotech, Foster City, CA, USA, #4311971). Condensation was prevented 
from forming on the inside of the slip by allowing the plates to acclimatize in a biological safety 
cabinet for 20-30 min. The excitation and emission filters were set to wavelengths of 488 nm and 
507 nm respectively to excite the eGFP and capture the resulting emissions of light. Values for 
relative fluorescence varied with sensitivity settings of the plate reader. Each plate was run using 
three different sensitivity settings and the highest-sensitivity data without any sensor overflow 
values (outputs of “overflow” rather than a quantitative measure of the fluorescence when the 
sensor is overwhelmed) used for analysis. Direct comparison was only possible with data 
collected using the same sensitivity. 
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4.6 Reverse transcription real-time polymerase chain reaction (RT-PCR) 
for gene transcript analysis 
All Polymerase Chain Reaction (PCR) experiments started with AV529-19 Vero cells seeded in 
a 6-well plate and infected once they reached full confluence. The seeding density and length of 
time the infection progressed in each well was dictated by the experiment being conducted. 
At 18 hpi, all wells’ media was aspirated and 1mL of TRIzol® reagent (Life 
Technologies Inc., Burlington ON, Canada, cat #: 15596-018) added. The TRIzol® was pipetted 
repeatedly and aggressively to lyse the cells, after which it was transferred to 1.5 mL microtubes 
(Corning Axygen, Union City CA, USA, cat #: MCT-150-C). After 5 min of incubation at room 
temperature (to allow for DNA disassociation) 200µL of Chloroform (Midland Scientific Inc. 
EMD, Davenport IA, USA, cat #: EMD CX1055-2) was added and the microtubes shaken 
vigorously for 15 seconds. The sample tubes were then centrifuged for 15 min at 12000 x g and 
4 
o
C to separate the mixture into three phases. The top aqueous phase was transferred to another 
1.5 mL sample tube without disturbing the other phases. 
RNA was precipitated using 500 µL of isopropanol. Tubes were incubated for 10 min at 
room temperature and then centrifuged at 12000 x g and 4 
o
C for 10 min. The RNA pellet was 
isolated by removing the liquid and washed using 75% ethanol. Once washed, the pellet was 
once again centrifuged at 7500 x g and 4 
o
C for 5 min before the wash was aspirated and the 
pellet air-dried for 5-10 min. The pellet was resuspended in 50 µL of RNase-free water (Life 
Technologies, Burlington ON, Canada, cat #: 10977-015) and then placed in a 55-60 
o
C water 
bath for 15 min to denature the RNA. RNA was converted to DNA using a High-Capacity cDNA 
Reverse Transcription kit (Applied Biosystems, Burlington, ON, Canada). 2 µL of each sample 
were mixed with 18 µL of reverse transcription (RT) mixture consisting of 2 µL RT buffer, 
0.8 µL of “dNTP” mix, 2 µL of RT random primers, 1 µL Multiscribe Reverse Transcriptase, 
and 12.2 µL of nuclease-free water. The mixing was done using the same microtubes which were 
then placed in a Bio-Rad T100 Thermal Cycler. Reverse transcription was achieved by holding 
the sample at 50 
o
C for 30 min followed by denaturation of the DNA for 5 min at 99 
o
C, and then 
cooling to 4 
o
C for storage. 
The qPCR reaction itself was conducted using an Applied Biosystems StepOnePlus RT-
PCR system (“StepOnePlus”). 2 µL of each sample were pipetted into the well of a MicroAmp 
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Optical 96-well reaction plate (Life Technologies Inc., Burlington ON, Canada, cat #: 
N8010560) containing 18 µL of primers and indicators. The exact composition of this mixture 
was 6.56 µL nuclease-free water, 10 µL of Power SYBR® Green PCR Master Mix (Life 
Technologies, Burlington ON, Canada, cat #: 4367659), and 0.72 µL of each of the forward and 
backward primers corresponding to the gene being tested (Table 1). The 96-well RT-PCR plate 
was then sealed using MicroAmp optical adhesive tape and placed in the StepOnePlus.  The real-
time PCR consisted of a pre-incubation at 95 
o
C for 10 min with a 4.4 
o
C ramp rate, followed by 
40 cycles of denaturation at 95 
o
C for 10 sec with a 4.4 
o
C ramp rate, annealing at 58 
o
C with a 
2.2 
o
C ramp rate, and elongation at 72 
o
C with a 4.4
o
C ramp rate. The PCR was terminated with 
cooling at 40 
o
C with a 1.5 
o
C ramp rate. 
Table 1: Reverse transcription primers used 
Primer Sequence Description 
RT GFP (forward) 5’ – CCT GAA GTT CAT CTG CAC CA – 3’ Primers used to quantify 
levels of eGFP RT GFP (backward) 5’ – GAA GAA GTC GTG CTG CTT CA – 3’ 
β-Actin (forward) 5′ – GGC CAG GTC ATC ACC ATT– 3′ 
Primers used to quantify 
levels of β-Actin 
β-Actin 
(backward) 5′ –ATG TCC ACG TCA CAC TTC ATG –3′ 
 
The amplification curves produced by the qPCR reaction were analysed using 
LinRegPCR software (available for free from www.hartfaalcentrum.nl). The software was used 
to set a common threshold fluorescence at which the gene amplification could be detected. The 
number of cycles required for each sample to reach this threshold was used as a “Cycle 
Threshold value” which could be used alongside the “effectiveness” of the amplification (factor 
by which each cycle increases the signal) to compare GFP and B-Actin expression. Ideal PCR 
reaction have an effectiveness of 2, meaning that the length of the cDNA chain increases two-
fold with each cycle, but LinRegPCR allows the true effectiveness to be used for more accurate 
results. The equation below was applied to calculate an effective “initial” level of fluorescence 
for GFP RNA. This level is proportional to the amount of GFP RNA which was present in the 
initial sample: 
𝑭𝑮𝑭𝑷
𝒐 = 𝑭𝜷−𝑨𝒄𝒕𝒊𝒏
𝒐
𝒆𝜷−𝑨𝒄𝒕𝒊𝒏
𝑪𝒕𝜷−𝑨𝒄𝒕𝒊𝒏
𝒆𝑮𝑭𝑷
𝑪𝒕𝑮𝑭𝑷
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In the equation above, 𝐹𝑥
𝑜  is the threshold level of fluorescence of a given protein’s 
RNA, ex is the effectiveness of the reaction for that protein, and Ctx is its threshold cycle value. 
The value calculated (𝐹𝐺𝐹𝑃
𝑜 ) was effectively the level of GFP fluorescence signal at the threshold 
cycle adjusted for the level of β-Actin signal. The 𝐹𝐺𝐹𝑃
𝑜 values were compared in a relative 
manner since the actual initial expression level of the GFP RNA was not being investigated here, 
only the relative degree of leakage. 
4.7 Immunofluorescent staining (IS) 
Vero cells were seeded on the surface of a glass cover slip (Globe Scientific Inc, Paramus NJ, 
USA, Item # 1404-15). This was accomplished by placing sterilized cover slips in the wells of a 
6-well plate and seeding the wells with the AV529-19 Vero cells at 1.5x10
5
 cells/mL. These 
were then incubated at 37 
o
C and 5% CO2 overnight to allow for cell attachment. After 
approximately 24 hrs the cells were infected with the ACAM529 virus at an MOI of 0.6-1.0 
(based on viral titers of 2-3 PFU/mL and a 1:10 dilution) and incubated for 1, 6, or 18 hpi. 
Cultures fixed at only 1 hpi were used to establish potential false-positive results as no progeny 
virus were expected to be observed at this time-point.  
Once ready, the cells were fixed using 2 mL of 4% paraformaldehyde added to the well 
to cease all biological activity at the desired point in the infection (20 min fixation). Cells were 
then flushed 7 times with PBS to remove as much of the fixative as possible. All washes 
consisted of adding 2-5 mL to each well, tipping the plate gently to move the liquid and then 
aspirating the PBS. One final 1-2 min soak with 1 M Glycine in PBS was also done to quench 
any residual formaldehyde. 
Cell membranes were permeabilized using Triton X-100 (Sigma-Aldrich, St. Louis MO, 
USA, cat. # X100-1L) at a concentration of 0.1% in PBS. 2 mL of the solution was added 
directly to the wells. Permeabilization lasted between 10 and 12 min after which the Triton X-
100 solution was removed and the cells washed 7 times with PBS. Once permeabilized the cells 
were blocked and stained.  
0.1% Tween 20 (Sigma-Aldrich, St. Louis MO, USA, cat. # P9416-100mL) and 1% 
Bovine Serum Albumin (BSA) (Sigma-Aldrich, St. Louis MO, USA, cat. # A1933-5G) in PBS 
(referred to collectively as PBS-T) was used to dilute all stains and blocking agents to maximize 
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their penetration into the Vero cells. Blocking was done using a solution of 10% animal serum 
(goat (Sigma Aldrich, Oakville ON, CA, cat. # G9023) and/or rabbit (Sigma Aldrich, Oakville 
ON, CA, cat. # R9133) serum depending on the antibodies used) in PBS-T for 45 min at room 
temperature. Enough of the blocking solution was added to each well to submerge the cover 
slips, which remained in the 6-well plate for this step to ease transportation.  
The cover slips were inverted over 60-100 µL of a solution of antibody in PBS-T for 45 
min at 37 
o
C to allow the antibody/stain to interact with the sample. The level of dilution was 
different for each antibody and was based on supplier recommendations, literature review, and 
personal experience. Between 100x and 500x dilution was the typical range used in this 
investigation. A separate staining step was required for each antibody and cell structure stain. 
Cells were rinsed 7 times with PBS after each staining step to ensure excess material was 
removed.  
Once staining was complete, the glass cover slips were inverted onto a glass microscope 
slide (Fisher Scientific, Whitby ON, CA cat #:12-544-1) and into one or two droplets (roughly 
80-120µL) of ProLong Gold Antifade reagent and mounting medium (Molecular Probes, Eugene 
OR, USA, cat. # P10144). The mounting medium was used to reduce bleaching, which can occur 
when the fluorophores are exposed to light. It also improved the refractive properties of the 
sample and ensured signal clarity. The mounting media required 12-18 hrs to cure before the 
cover slips could be sealed with nail polish (Extra Life No Chip Top Coat, Revlon Consumer 
Products Corporation, New York, New York) to prevent the samples from drying out. Once 
sealed, the slides were ready for imaging. 
4.7.1 Establishing noise levels and assessing experimental controls for viral protein 
immunofluorescent staining 
AV529-19 Vero cells were grown on glass slides as described in Section 4.4. ACAM529 HSV 
virus was used to infect half of the cells at an MOI of approximately 1 and infection was allowed 
to progress for 1 hour. The other cover slips remained uninfected. The cells were then fixed, 
permeabilized, and one of each slide was stained with each of the primary antibodies listed in 
Table 2 at the concentrations listed therein. Each staining step was conducted for 45 min at 
37 
o
C. Cells stained with a-gE+FITC underwent no secondary staining while cells stained with a-
gD, a-gB, a-gC, a-ICP5, a-ICP27, and a-Poly all underwent secondary staining with a-Mouse 
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AlexaFluor 488 for 45min at 37
o
C. Lastly, each cover slip was stained with CellMask at a 
concentration of 1:500 for 5min. 
Table 2: Information on antibodies used in Section 6.2 experiments 
 
Imaging was done within 48 hours of the completion of the staining to minimize the risk 
of fluorescence degradation. Laser strength was not changed throughout the experiment to 
minimize inconsistencies between samples. Brightness and contrast modifications were made 
using the built-in settings of the Zeiss Zen 2009 software (Section 4.7). 
4.7.2 IS antibody panel to determine efficacy at 6 and 18hpi 
AV529-19 Vero cells were grown on glass slides as described in Section 4.4. ACAM529 HSV 
virus was used to infect the cells at an MOI of approximately 1 and infection was allowed to 
progress for either 6 or 18 hours. The cells were then fixed, permeabilized, stained, and imaged 
as per Section 4.4.1. 
4.7.3 a-ICP5 and a-gE+FITC co-staining for mature viral particle identification 
For this investigation, AV529-19 Vero cells were grown on glass slides as described in Section 
4.4. ACAM529 HSV virus was used to infect the cells at an MOI of approximately 1 and 
infection was allowed to progress for 20 hours. The cells were then fixed, permeabilized, and 
stained with a-ICP5 (at a dilution of 1:100), a-Mouse AlexaFluor 405 (1:500), and a-gE+FITC 
(1:500). Staining steps were all carried out for 45 min at 37 
o
C. The cells were also stained with 
either CellMask cell membrane stain (1:500 dilution, 5 min at room temperature) or Cytopainter 
Phalloidin-iFluor 647 Reagent F-actin stain (1:500 dilution, 45 min at 37 
o
C). No infection and 
2 hpi controls were also stained to capture the level of background and/or non-specific staining. 
Imaging and image analysis was conducted as per Section 4.4.1. 
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4.8 Microscopy 
Two microscopes were used in this body of work. The first was a dual inverted light and 
fluorescence microscope that allowed a sample to be visualized under one of three fluorescence 
excitation filters or using white light. This was achieved using a Zeiss Axiovert 200 inverted 
light microscope with an attached Zeiss HBO 50 burner mercury lamp and filters. This 
microscope allowed for imaging at 50x and 100x magnification and was used to track cell 
confluence and the progress of infection. In cases were infection was expected to produce 
fluorescence, both light and fluorescence imaging could be carried out on the same sample. 
Images from this microscope were captured digitally using the “.raw” format. 
The second microscope used was a LSM 510 META confocal microscope from Zeiss. 
The confocal microscope provides a clear image of a very thin cross-section of a sample. The 
images themselves are composed section by section digitally as a pair of scanning mirrors moves 
the excitation laser across the sample. The resolution was set manually and is inversely 
proportional to the time required for the image to be compiled. 
The LSM 510 META was equipped with oil immersion objectives which allowed for 
imaging at 40x and 63x magnification. Images were captured using Zeiss Zen 2009 software in 
“.LSM” format. 
Images taken using the Axiovert 200 were modified using ImageJ (National Institutes of 
Health, Maryland, USA, public domain software package), a free image processing and analysis 
software available online. The digital settings (brightness and contrast) were adjusted using 
Zeiss’ Zen 2009 software for each image individually in order to capture the best images 
possible in terms of signal strength and clarity. The software uses several pre-set options which 
were used for fast and consistent processing. Each image was captured after a “Min/Max” or 
“Best Fit” adjustment had been made to ensure that signals of different strengths could be 
observed. Both of these adjustments are pre-set in the software and affect only the image’s 
display options, not the data itself [229]. The “Min/Max” option provides the best balance of 
signal and background noise and is optimal to isolate strong signals. The “Best Fit” option 
attempts to capture as much of the signal possible, making weak signals easy-to-see, but also 
resulting in high background noise.  
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4.8.1 Quantitative image analysis 
Several features of the ImageJ software were used to produce quantitative data for images which 
could then be compared in a more rigorous fashion. It allowed for high fluorescence intensity 
regions of images to be isolated and quantified. The qualitative data then allowed for more robust 
analysis. 
ImageJ was used to set a threshold on signal strength on a pixel-by pixel basis. Once a 
threshold had been established (the criteria being subjective but consistent among the images 
analysed), the software set all pixels meeting the threshold to white and everything else to black. 
By determining what fraction of the pixels were “on” or “off”, the program determined the 
percent of the image area which met the threshold criteria. As long as the brightness threshold 
remained consistent between images, this provided an accurate quantitative method of 
comparison between the infected and uninfected cell fluorescence. Displaying the entire image 
area to a binary colour-coded manner also benefitted quantitative analysis by simplifying the 
image and ensuring consistency (through consistent thresholds). 
4.9 Vero cell culture insert culturing, infection, and staining 
All cell culture insert experiments involved the culturing of HSV2013-121 Vero cells in both  1.0 
µm PET transparent cell inserts (Millipore, Switzerland, Cat. No. PIRP30R48) and in  wells of a 
6-well cell culture plates (Thermo Scientific Nunclon, Roskilde, Denmark, Cat. No. 140675). 
The two were seeded concurrently in separate 6-well plates and then allowed to adhere and grow 
to confluence. Both the well culture and insert culture could be tracked visually using an inverted 
light microscope in order to ensure confluence. Once the monolayer has completely formed, the 
cell in the insert could be infected with ACAM529 HSV. 
The insert and well cultures remained separate when the “primary infection” was 
conducted. 1mL of diluted viral stock (dilution based on experiment goals) was added to each 
cell insert and 1 hr was allowed for viral attachment. After 1hr the infection media was aspirated 
and replaced with sterile DPBS. The inserts were then moved to another cell culture plate 
containing only DPBS. DPBS was used to remove as many un-fused virus particles from the cell 
monolayer, insert membrane, and insert surfaces as possible. After being washed two more times 
with fresh DPBS the insert culture was covered with plaque overlay media (standard DMEM 
Vero cell culture media with 0.75% methyl cellulose) to prevent virus particles from travelling 
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through the supernatant. Once this was done the insert was moved to the 6-well culture plate 
containing the well cultures. 
 
Figure 8: Cell culture insert experimental protocol diagram 
 
4.9.1 Validation of cell culture insert membrane as a valid Vero cell substrate 
A 6-well cell culture plate and set of cell culture inserts were seeded at 2x10
5
 cells/mL as per 
Section 4.8. 2mL of cell suspension were added to each culture plate well and 1.5mL to each cell 
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insert. After 24hrs of incubation both sets of cultures were imaged using an inverted light 
microscope after which the insert cultures were infected at a 1:10 dilution of viral stock. The 
exact viral titer was not determined for this investigation. Once the one-hour virus attachment 
step was complete, the inserts were washed and moved to the well culture plate.  
One of the insert cultures was not infected (as a control) and imaged immediately instead 
of being transferred to the well culture plate. The remaining inserts were allowed to remain in the 
well culture plate for 12, 15, 18, and 20 hrs. At each time point the corresponding cell culture 
insert was removed from the well culture plate and both well and insert cultures were imaged.   
4.9.2 Determining infective titer reduction between primary and secondary infection for 
infected cell culture inserts 
Two 6-well culture plates and 12 cell culture inserts were seeded at 2.5x10
5
 cells/mL, 2 mL into 
each culture plate well and 1 mL into cell insert. An additional 12-well culture plate was seeded 
at the same density for a concurrent plaque assay. The cells were incubated for 24 hrs and the 
confluence of the monolayers was confirmed visually prior to initial infection. Virus serial 
dilutions were prepared within 30 min of infection to minimize degradation. The serial dilutions 
used for infecting cell culture inserts were 10
-1 
(1:10), 10
-3
, and 10
-5
. Six inserts were infected at 
10
-1
 and three were infected with each of the other two dilutions. Three wells (one column) of the 
plaque assay plate were infected with each of no virus, 10
-4
, 10
-5
, and 10
-6
. 200µL of the 
corresponding viral dilution was used to infect each plaque assay well, and 1 mL was used to 
infect each cell insert. 
The plaque assay’s uninfected wells served as a negative control for viral infection the 
experiment. Three of the six cell culture inserts infected at 10
-1
 were allowed only one hour in 
their corresponding well culture (after the one hour of virus attachment and washing steps). This 
“2hpi” control served as a measure of how many virus particles from the initial infection could 
be found in the well cultures. Two hours was not enough time for progeny virions to form, 
meaning all plaques formed in these wells had to be formed by viral particles added to the cell 
culture insert and not removed by washing. Plaque overlay media was added to the plaque assay 
plate at 1hpi and to the 2hpi well cultures at 2hpi.  
All other cell inserts were removed from their corresponding well cultures at 20hpi. 
Plaque overlay media was added to these wells and the cell culture inserts were moved to another 
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6-well culture plate. All cultures (both insert and well) were then allowed 48hrs for plaque 
formation before being stained with Crystal Violet for 30min. Plaques were counted using visual 
inspection and the viral titer calculated as per the plaque assay protocol.  
The length of time for which infected inserts remained in the well culture plate was 
dictated by the goals of the experiment being conducted. During this time, any viral particles 
budding in a direction of the force of gravity towards the well culture could infect its cells. As 
long as the infected inserts were removed before this secondary infection could produce further 
(tertiary) progeny viruses, the number of virus particles descending from the insert could be 
quantified by removing the insert and replacing the cell culture media with plaque overlay 
media. Both insert and well cultures were stained with Crystal Violet 48hrs after plaque overlay 
media was added, allowing the same amount of time for plaque growth as in the methodology 
(Section 4.2). Counting these plaques (along with those in control wells) allowed the number of 
infective virus particles that budded downward to be quantified. 
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Chapter 5 – Virus Infection and 
Quantification using Fluorescent 
Protein Expression 
HSV2012-121 is a Vero cell line capable of allowing the replication of ACAM529 that also 
contains the gene for enhanced green fluorescence protein (eGFP) under the viral promoter 
which controls ICP10. In theory, eGFP expression should only occur upon infection of the cell 
with a virus encoding a viral polymerase that recognizes the infected cell protein 10 (ICP10) 
gene’s promoter sequence. The objective of this chapter was to establish protocols to monitor the 
infection of HSV2012-121 with ACAM529, and determine the feasibility of using these 
protocols as part of an end-point dilution assay (EPDA). The motivation for this work was the 
time and labour-intensive nature of the current best method for virus quantification (the plaque 
assay) which makes investigating the system more difficult. 
Protein expression can be achieved by stably transfecting a cell line with a reporter 
protein gene under the control of a viral promoter. Viral promoters, as referred to here, are 
sequences that “promote” gene expression but that require a viral RNA polymerase that is only 
brought to the cell by means of the virus. Thus, under normal conditions (i.e. no virus infection), 
the cell does not express an RNA polymerase that recognizes the promoter sequence. Upon 
infection, the viral polymerase becomes available and the reporter protein is expressed in the 
cell. This type of system is one that can then be used to understand how the cell becomes 
infected and how long it takes for expression of genes under particular promoters or, 
alternatively, can be simply used in virus titration. 
The importance of measuring virus titer accurately in research and industry applications 
cannot be overstated. The extremely small size and unstable nature of virus particles present an 
interesting challenge for enumeration, which has resulted in the development of many assays. In 
most cases, the virus is enumerated in an indirect manner and the titer is expressed in plaque-
forming units or TCID50 rather than the actual particle density.  
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Alternative titration methods are always being sought to replace the Plaque Assay, which 
is still the most relied upon titration method used in industry. The protocol, outlined in Section 
4.2 requires four days to complete and relies on operators to recognize individual plaques. 
Plaques are generally visualized using Crystal Violet (ammonium oxalate), which can damage 
aquatic environments if improperly disposed of, and can be carcinogenic [230]). 
5.1 Determining fluorescence threshold indicative of infection 
A known high-fluorescence system composed of SF900 insect cells and a GFP-producing 
Baculovirus construct was used as a positive control for the use of the Spectrofluorometer (as per 
Section 4.1.2). In this investigation, a 96-well plate was seeded with Sf9 cells and infected as per 
Section 4.5.1. This was done to determine the extent to which wells showing fluorescence could 
be differentiated from uninfected ones using a spectrofluorometer. This effectively served as a 
positive control for EPDA experiments using this methodology. 
Daily observations of the fluorescence under the light microscope showed that the 
infection spread very slowly in low MOI wells. While some fluorescence was observed within 
the expected 20 hpi, the wells infected at 1:1000 (referred to as “10-3” wells) dilution and below 
did not show pervasive infection until 3 days post infection (dpi). Those wells infected with 
1:10,000 (10
-4
)
 
and 1:100,000 (10
-5
) viral dilutions showed signs of infection by 3dpi but 
required up to 10 days before the fluorescence spread to a significant portion of the well.  
By 6dpi, high cell death and lysis were observed in those wells infected at 10
-2
 and 10
-3
. 
This was in line with what had been observed in infected cell culture time course experiments in 
which high to moderate MOI resulted in almost complete culture death by 4dpi (Figure 9). The 
level of fluorescence in the highly infected wells was substantially lower than those in the well 
infected at lower MOIs (Figure 10). However, the eGFP was sufficiently stable in the 
extracellular environment to remain easily detectable and the loss in overall fluorescence did not 
result in false negatives in these wells. 
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Figure 9: Viable cell count over time for an infected adherent Sf9 cell culture according to MOI (n=3) 
At 10 dpi, the plate data was analysed to establish the level of fluorescence which could 
be deemed “positive” for infection. The data was split into “infected” and “uninfected” 
categories using visual observation of cytopathic effect and fluorescence, after which the two 
sets of data were used separately in the analysis.  
Two outliers (over two standard deviations from the mean) were found at 10 dpi in the 
infected wells. The average fluorescence level of the remaining 48 infected wells (excluding the 
outliers) was 2.4x10
7
 relative fluorescence units (RFU) with a standard deviation of 6.7x10
6
 
RFU, which represents 27.3% of the total average fluorescence. The average uninfected well 
fluorescence was 3.7x10
6
 RFU, which was roughly an order of magnitude lower than the 
infected average and lower than the standard deviation of the infected wells. The deviation of the 
uninfected wells (n=46) was much tighter at 2.8x10
5
 RFU or 7.7% of the average level.  
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Figure 10: Sf9/Baculovirus EPDA Infected well fluorescence with LoD and LoQ 
The limit of detection (LOD) and limit of quantification (LOQ) for the assay were 
calculated using the RFU measurements in the uninfected wells at 10dpi in order to determine 
the level of fluorescence which can be said with statistical cetainty to differentiate them from the 
infected wells. The low variability in the uninfected wells, these limits were very close to the 
average uninfected well RFU, indicating an effective assay. Only one of the outliers identified in 
the infected well data fell below the limit of quantification. This meant that even with the 
relatively high variability observed in the infected well fluorescence, this assay could distinguish 
all but one of the wells correctly at 10dpi. 
Applying the LOD to the data collected at 3, 6, and 10dpi, the viability of the assay was 
determined at earlier time points. Comparing the titers to the one caclucated using visual 
inspection it was found that even at 10dpi the titer calculated from RFU data was 11.8% below 
the actual titer of the assay. At 3 and 6dpi this difference was much higher at -69.15% and -
55.3% error respectively. The errors in titer were all negative, indicating that only false negatives 
were observed in the data (infected wells not exibiting high enough RFU values for the assay to 
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indicate an infection). Due to this oberved one-sided nature of the error, the use of a single 
criterion for determining the presence of infection (the LOQ) was justified. 
 
Figure 11: Sf9/Baculovirus EPDA Average Fluorescence (n=12 for each infection titer, titers expressed in scientific notation 
depicting the dilution (1E-02 = 10
-2
) 
While eGFP was found to be fairly stable over the 10 day period, the wells in which it 
was evident later on were found to be more fluorescent at 10dpi. The difference was only 
statistically significant between the highest MOI wells (10
-2
) and those infected at 10
-3
, 10
-4
, and 
10
-5
, with the latter three not completely differentiable from each other. The increase in the 
standard deviation of the RFU values with decreasing MOI was noticeable between the first four 
MOIs (as seen in Figure 12). These results were attributed to differences in the infection spread, 
with high MOI wells infected much more synchronously while lower-MOI wells required several 
viral replication cycles to become highly infected. The results also indicated synchronous 
infection resulted in lower RFU readings at 10dpi. Large differences in MOI are inherent in the 
EPDA, meaning that this trend was expected for all such assays. 
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Figure 12: Sf9/Baculovirus EPDA fluorescence standard deviation values (n=3 for original fluorescence data) 
The original intention was to use the high-fluorescence Sf9/baculovirus system to 
establish a positive control for the EPDA. This system yielded relatively accurate titers at 10dpi 
and validated the use of a spectrofluorometer in this assay. Some issues did exist applying the 
results of the above experiment to a completely different virus/cell system. Not only does the 
manner in which infection spreads vary between viruses, but the autofluorescence of the cell 
culture can also be quite different. Whether this was due to differences in the cells themselves or 
in the cell media it could result in issues for the assay. 
5.2 Quantifying HSV2012-121 and media autofluorescence  
To establish appropriate negative controls for the HSV2012-121/ACAM529 system, a closer 
examination of the fluorescence of the cell culture media and cells was conducted. In particular, 
the background fluorescence of the mammalian culture media and the cells themselves needed to 
be established.  
Cell culture media can contain a wide variety of additives with fluorescence of their own 
including tryptophan, pH buffers like Phenol Red, and others. A first hypothesis which was to be 
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tested was that it may be possible to overcome media autofluorescence in the assay by removing 
the media and replacing it with a liquid that had lower autofluorescence. 
Cells can also contribute to the fluorescence signal through what is known as “DNA 
leakage”, or the production of a gene product without active stimulation of its promoter. It is 
possible for eGFP to be produced in the HSV2012-121 Vero cells even without an HSV 
infection. The level of the background fluorescence has to be quantified for a given system 
before its usefulness in an assay can be determined. Otherwise, it is difficult to say what level of 
fluorescence corresponds to an infection rather than to naturally occurring fluorophores. 
Furthermore, the background fluorescence and internal variability of the plate reader itself also 
has to be considered. 
Using a clear-bottom 96-well plate, different combination of cells and liquid were 
examined for their fluorescent properties. The volume of liquid in each well was kept at 100µL 
except in the empty control wells. The wells containing cells and media were prepared roughly 
24 hrs before the rest of the plate to allow for cell attachment. Wells already filled had their 
media aspirated and replaced to ensure that evaporation did not cause changes in volume.  
Vero cells in DMEM were considered the “standard condition” given that this was the 
initial setup for the EPDA. Vero cells in overlay DMEM media (as per the Materials and 
Methods) was investigated as an alternative for regular DMEM. DMEM and overlay DMEM 
alone were investigated toprovide information on their autofluorescence. Dulbecco’s Phosphate 
Buffered Saline (DPBS) and highly purified (MQ) water respectively were also investigated. 
This was done so that the autofluorescence of each liquid to be determined and compared both to 
the DMEM and overlay media and to the Vero cell autofluorescence calculated. 
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Figure 13: Average background fluorescence of Vero cells, cell media, and media alternatives (n=3, blank indicates the 
fluorescence in well that were empty) 
Figure 13 shows the average fluorescence of media compared to other potential liquids 
that could be used to cover/host the cells. Replacing the DMEM media by either DPBS or MQ 
water could enhance the ability to detect eGFP significantly.  However, there is a chance that 
replacing the media could result in loss of the protein released into the media through lysis, as 
well as loss of the cells themselves which have detached from their substrate as a result of 
infection(as seen in the insect cell infections where most cells have completely lysed).  
As observed in Figure 13, the presence or absence of Vero cells did not affect the RFU 
values in DMEM and overlay media to a statistically significant degree. While the overlay media 
displayed a lower level of fluorescence than the DMEM in the presence of cells, the same could 
not be said about fluorescence of the two types of media in the absence of cells. For this reason, 
neither of the DMEM media variations had a statistically significant higher level of relative 
fluorescence. 
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5.3 Monitoring ACAM529 virus infection of HSV2012-121 cells using eGFP 
expression 
The purpose of this experiment was to determine if the level of fluorescence of infected Vero 
cells could be discerned within a single cycle of infection and whether varying the MOI would 
result in detectable variations in fluorescence. Vero cells (HSV2012-121) were infected with 
ACAM529 at three different MOIs, diluting a virus stock with an approximate titer of 2-3x10
6
 
pfu/mL by a factor of 10
-1
, 10
-2
, and 10
-3
. The expected MOIs were between 0.8 and 1.2, 
meaning that ~37% of cells would remain uninfected after the initial round of infection [2]. 
While the MOIs used could not be expected to result in synchronous infection (all cells infected 
at the same time rather than through multiple cycles of infection and virus replication), eGFP 
production was expected throughout the plate by 24hpi (since 24hrs is sufficient for the virus to 
undergo a single replication cycle and for a secondary infection cycle to begin).  
An additional row of wells was seeded with Vero cells but not infected, which was used 
as a negative control for infection. Two rows of wells were filled with DMEM media (no Vero 
cells) and one row with MQ water to minimize evaporation and provide a gauge for the level of 
experimental (equipment) noise. The fluorescence of all wells was then read at 24 hours post-
infection.  
 
Figure 14: Average fluorescence of infected HSV2012-121 cells at 24hpi (n=8) 
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Unlike in an EPDA protocol, the MOIs used for this experiment resulted in most cells 
being infected, showing signs of cytopathic effect, and fluorescing by 24hpi. There was no 
statistically significant change in the RFU values observed at this time (Figure 14).  
In an attempt to simplify the analysis, the fluorescence associated with infection was 
isolated by subtracting the average fluorescence of uninfected wells from that of the infected 
wells. Only those wells infected at the 10
-3
 dilution of virus stock had a difference in 
fluorescence from the uninfected wells that exceeded one standard deviation of the original data. 
As demonstrated in Figure 14, the infected wells could not be differentiated from the uninfected 
wells with any degree of statistical certainty. Whether this was caused by high autofluorescence 
or expression of eGFP in uninfected wells needed to be determined.  
5.4 Alternative culture and infection conditions to enhance detection of eGFP 
To determine if smaller volumes of media could be used to reduce the effect of background 
fluorescence Vero cells were infected with identical virus solutions in either 50 or 100 µL 
DMEM or DMEM Overlay media. Fluorescence data was collected using the spectrofluorometer 
at 24, 48, and 96hpi. As with the previous experiment, the majority of the cells were expected to 
become infected and fluoresce within 24hrs. Readings at later time points were taken to test this 
hypothesis and determine if any conclusions could be made about eGFP stability. 
Uninfected wells containing Vero cells and each one of the media/volume combinations 
tested were used as negative controls for autofluorescence as well as evaporation (given that 
there were no changes occurring in these wells due to infection). Several rows of wells were 
filled with MQ water providing a control for internal variability of the equipment.  
The 4-day changes in fluorescence were either negative or negligible in spite of 
adjustments made to minimize and account for evaporation. All changes were within a single 
standard deviation of the average RFU and were therefore not statistically significant even in the 
most lenient sense.  
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Figure 15: Fluorescence of infected and uninfected Vero cells in DMEM and overlay media (inf = infected, uninf = 
uninfected, n=3) 
When 100µL of DMEM was used, the presence of infection was completely indiscernible 
from the uninfected control. Reducing the volume improved the separation slightly, but even in 
the best case scenario the fluorescence of the infected wells was not better than the established 
background. This together with the data presented above points to a weak level of eGFP 
expression that does not allow for the tracking of infection under the conditions used. 
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Figure 16: Uninfected Vero cells light (A), infected Vero cells light (B) and infected Vero cells fluorescence (C) 
images (images B and C are taken of the same section of the sample) 
Images of the infected cell culture plate were taken at 24 hpi using the light and 
fluorescence microscope (Figure 16B and C) to ensure that the level of infection was as high as 
expected and that it was not a lack of infection that was causing the weak fluorescence signal. As 
the images show, by 24 hpi, all the cells showed extensive cytopathic effect (the visible effect 
which a virus has on the host cell which it is infecting) and the culture was unmistakeably altered 
from its healthy state (Figure 16A). The rounding and enlargement of the cells indicated a mid to 
late-stage infection with HSV-2. The fluorescent protein (eGFP) was being expressed, but the 
majority of the fluorescence in the image would not have been visible if the brightness and 
contrast had not been adjusted. 
Given that an EPDA involves non-synchronous infection in which evaporation and cell 
lysis has been seen to lead to further reduction in signal strength, the issues described would be 
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further compounded if the Vero/HSV system was titrated with this method. Unless eGFP signal 
strength could be improved in some way, this system is not suitable for the EPDA. 
5.4.1 Enhancing eGFP expression 
Section 5.1 demonstrated the spectrofluorometer’s ability to identify separate infected from 
uninfected wells based on their fluorescence in an EPDA with Sf9 cells as a positive control. 
Unfortunately, the same instrument was unable to discern a statistically significant difference in 
the RFU values of infected and uninfected HSV2012-121 Vero cells, as seen in the previous 
section. Several approaches were considered for overcoming the issue of weaker fluorescence 
signal. Given that fluorescence was detected by inverted fluorescence microscope it was known 
that some increase in fluorescence did indeed occur. Using more sensitive equipment could have 
allowed this difference to be quantified, but such equipment was neither available nor known for 
certain to exist. 
The other logical way to detect the infection’s effect on fluorescence was to increase this 
effect. One substance which has been used to enhance GFP transcription in adherent cell culture 
without altering the genetic information is Sodium Butyrate (NaBu) [231]. While high 
concentrations of this compound are lethal to the cells, at low concentrations it causes increased 
stationary phase nutrient consumption and hyperacetylation of the cells’ histones, which results 
in increased protein production [232, 233]. The challenge in my work was then to balance the 
signal enhancement with the health of the cells. 
A major concern with the use of a compound like NaBu stems from its inherent 
indiscriminate nature in terms of protein production enhancement. ”Expression leakage”, 
resulting from the cell’s ability to transcribe from the viral promoter, can result in eGFP being 
produced in cells not infected by HSV. This undesired expression could be enhanced too, 
resulting in higher background levels of fluorescence not associated with infection. Balancing 
this background noise enhancement against the improvement of the actual fluorescent signal was 
therefore a priority in this investigation. 
5.4.1.1 Fluorescence Protein Expression Leakage 
To quantitatively determine the extent of the ‘leakage’ of eGFP, the transcription levels of its 
gene in infected and uninfected cells were analyzed. Reverse transcription real-time polymerase 
chain reaction (RT-PCR) was used to amplify and detect any ribonucleic acid (RNA) 
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corresponding to the eGFP gene. Ideally, no eGFP RNA would be present in any cells not 
infected with ACAM529.  
β-Actin, a major structural component of animal cells, was used as a control to account 
for the number of cells from which RNA was being extracted. Since genes coding for β-Actin 
should be expressed at comparable levels in all Vero cells, β-Actin mRNA was used to 
standardize the eGFP readings. Both infected and uninfected HSV2012-121 along with 
uninfected AV529-19 were analysed for both eGFP and β-Actin.  
 
Figure 17: Translated and Normalized Reverse Transcription Polymerase Chain Reaction Data (Cycles 20-40) (NI = 
No infection, hpi = hours post-infection) 
Figure 17 shows the portion of the RT-PCR data in which the signal became detectible 
(the point where it becomes detectable is known as the Cycle Threshold). AV529-19, the cell 
line containing no eGFP, was used as a control and shows the level of background noise in the 
experiment. The sample with no eGFP expression reached the detection threshold at roughly 32 
cycles. The uninfected HSV2012-121 Vero cells reached the same threshold at about 24 cycles, 
only 2 cycles after the infected HSV2012-121. The LinRegPCR data analysis yielded similar 
results. The estimated level of GFP ribonucleic acid (RNA) in the infected HSV2012-121 cells 
was 595.28 times higher than that of the uninfected AV529-19 control (based on the cycle 
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threshold). The uninfected HSV2012-121 cells had an estimated level of GFP RNA 50.63 times 
higher than the control. The difference between infected and uninfected HSV2012-121 cells was 
only 11.74 times the GFP RNA. 
The RT-PCR provided evidence of GFP gene expression leakage in the 
ACAM529/HSV2012-121 system. This leakage resulted in data not matching the negative 
control (a cell line completely devoid of GFP expression). While RT-PCR could differentiate 
between the infected and uninfected fluorescent cells’ GFP expression, the levels of expression 
were much closer between the infected and uninfected HSV2012-121 cells than they were to the 
control.  
5.4.1.2 NaBu Addition Window and Concentration Optimization 
Since cell death due to NaBu toxicity would become confounded with viral cell death in an 
infected Vero cell system, uninfected cells were used for establishing an optimized protocol. 
This approach allowed differences in the health of cells to be more accurately attributed to the 
presence of NaBu and the level of eGFP expression leakage could also be monitored. Without 
the presence of ACAM529, fluorescence detected could be attributed to the leakage.  
Two addition (or “spiking”) times were tested for the NaBu, at the time of Vero cell 
seeding and 24 hrs after seeding. The cells were imaged using both fluorescence and light 
microscopy and the images compared to determine the optimal conditions. While spiking on 
seeding may integrate more easily with the existing protocol, it does not allow time for the cells 
to attach and become confluent before exposure to the toxicity of the NaBu. On the other hand, 
spiking at 24hrs after seeding would extend the protocol a further 24 hrs to allow for the NaBu to 
enter cells before infection with the virus.  
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Figure 18: Cell Culture Spiked at Seeding Light Images 48hrs after seeding (0mM (A), 1mM (B), 2mM (C), 3mM 
(D), 4mM (E), 5mM (F)) (40x magnification) 
The effect of the NaBu was apparent in Figure 18. The culture was completely confluent 
and the cell density was very high when no NaBu was present (Figure 17 A). Very few of the 
cells were rounded and detached, as is expected of a healthy Vero cell culture. As the 
concentration of NaBu increased the cells become more and more affected by the toxicity with a 
higher number of detached cells (Figure 18 B-F). Full confluence as maintained at NaBu 
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concentrations below 3mM despite this toxicity, indicating that the majority of the cells were still 
attaching to the culture plate surface normally and replicating. At concentrations above 3mM the 
cell death becomes significant and confluence was not full. In spite of this, the cells which 
remained attached remain healthy. 
 
 
 
Figure 19: Cell Culture Spiked at 24hrs after Seeding Light Images 48hrs after seeding (0mM (A), 1mM (B), 2mM 
(C), 3mM (D), 4mM (E), 5mM (F)) (40x magnification) 
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Figure 19 shows the cells spiked with NaBu at 24hrs after seeding. The amount of cell 
death in the high NaBu concentration wells of the 24hrs after seeding plate was much higher than 
those seen in Figure 18 B-F. In fact, the adherent culture was difficult to distinguish past all of 
the detached cells in Figure 19F. At NaBu concentrations of 2mM and below, the culture was 
similar to the ones spiked at seeding. Full confluence was maintained until 4mM NaBu (Figure 
19E), which was slightly better than the cells spiked at seeding (which were only confluent to 
3mM). 
The light images in Figure 18 and Figure 19 demonstrate the significant toxicity of NaBu 
to Vero cells at concentrations of 3mM and above. Both methods of adding the NaBu showed 
this toxicity with those cells spiked at 24hrs after seeding having the larger number of dead cells 
at 48hrs. NaBu addition 24 hour post seeding maintained confluence at slightly higher 
concentrations of NaBu, likely because the cells were given time to attach to the cell culture 
plate. After 48hrs, the cells were analyzed for fluorescent protein expression using inverted 
fluorescence imaging.  
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Figure 20: Cell Culture Spiked on Seeding Fluorescence Images 48hrs after seeding (0mM (A), 1mM (B), 2mM (C), 
3mM (D), 4mM (E), 5mM (F) NaBu) (40x magnification) 
The images in Figure 20 were highly altered in terms of brightness to clearly visualize the 
fluorescence. The fluorescence was strongest (relatively) in the 5mM NaBu well (Figure 20F). 
Expression leakage was present in the control well and its brightness increased with NaBu 
concentration. The fluorescence did not increase observably until 2mM NaBu, with a sharp rise 
in the fluorescence around 2mM or 3mM NaBu. The increase in fluorescence mirrored the 
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increase in toxic effect on the cells observed in Figure 18. By 5mM NaBu, the level of 
fluorescence was comparable to that of infected cells (Figure 16C). While not every cell in any 
image of Figure 20 displayed a high level of brightness, those that did would definitely create a 
high level of noise in an End Point Dilution Assay.  
 
Figure 21: Cell Culture Spiked 24hrs after Seeding Fluorescence Images 72hrs after seeding (0mM (A), 1mM (B), 
2mM (C), 3mM (D), 4mM (E), 5mM (F) NaBu) (40x magnification) 
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The increase in leakage was also observed in samples spiked with NaBu 24hrs after 
seeding. The increase seemed more gradual than the wells spiked on seeding (Figure 20) and the 
highest fluorescence (at 5mM NaBu) was less bright than for samples spiked at the time of 
seeding. Figure 21 also did not demonstrate the same leap in increased fluorescence between 
2mM or 3mM NaBu that was observed in Figure 20 and both sets of light images. There was 
very little observable difference between the fluorescence at 4mM and 5mM NaBu for this plate 
(Figure 21 E and F). 
The eGFP production of this system was significantly leaky with fluorescence detectable 
in the absence of HSV infection or NaBu. The leakage was most noticeable at concentration of 
3mM and above, where it became almost as bright as that which was observed in infected cells 
without NaBu. NaBu’s effect on the cells was most notable at concentrations of 3mM and above. 
Adding the NaBu at the time of seeding resulted in the more notable enhancement in protein 
production.  
The toxicity of the NaBu resulted in high cell death at 4mM and 5mM NaBu after 24 
hours. Although those samples spiked with NaBu 24 hours after seeding showed higher number 
of dead cells, they also had a higher degree of confluence at the highest concentrations of NaBu. 
Given the higher level of protein production enhancement when NaBu spiking at seeding 
coupled with the comparable cell death and confluence, it was judged that NaBu spiking at 
seeding was the more effective method. Concentrations of NaBu between 2 and 4mM were 
selected to be the best balance between protein production enhancement and cell death. As long 
as the enhancement of the fluorescence was more significant for infected cells than it was for 
uninfected leakage, NaBu spiking of the media showed potential for being the signal 
enhancement which was required for the EPDA to be effective. 
5.4.1.3 NaBu Response in Infected Cell Culture 
Having established the NaBu concentrations and NaBu spiking method which seemed to result in 
the best balance of protein production enhancement and cell death, the NaBu spiking could be 
applied to infected cells. Higher eGFP production was only useful for the improvement of the 
EPDA if infected cell fluorescence was improved more than uninfected eGFP expression 
leakage. This would make the infected wells more easily discernible from the uninfected wells 
using the plate reader.  
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The cells were imaged using fluorescence microscopy at 12hpi (36hrs after seeding). This 
was enough time for eGFP to be expressed in infected cells and as close to the time after seeding. 
The fluorescence of the infected Vero cell culture was far more easily imaged than the leakage 
which was analyzed in the experiment, allowing for the larger magnification to be used. Even 
without any digital optimization the infection could be easily tracked using the fluorescence 
microscope and the bright fluorescent signal. 
  
  
  
Figure 22: Infected Vero Cell Culture at 12hpi with Original Image on the Left and White/Black on the Right 
(0mM NaBu (A), 2mM NaBu (B), and 4mM NaBu (C)) (40x magnification) 
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The Vero cells showed a synchronous infection with a high level of eGFP expression 
even at 12hpi. Figure 22 can be used to make observations on the culture in general and not just 
the fluorescence. The health of the cells was seen to deteriorate significantly as the concentration 
of the NaBu increased. Cells are more detached, and even stop adhering to each other as their 
structure breaks down. Without NaBu, the cells showed a high level of confluence expected early 
on in the infection. At 2mM NaBu the cells appeared to be detaching from the culture plate and 
clumping up, a state usually observed at 20hpi or more. The cells in the culture spiked at 4mM 
NaBu displayed almost complete detachment and an almost complete lack of cell junctions. 
NaBu seemed to accelerate the process of cell death due to infection. 
The fluorescence was likewise clearly influenced by the NaBu concentration. Figure 22A 
shows a fairly low level of fluorescence with only a few points meeting the level in Figure 22B 
and C. The latter two cultures on the other hand had a much more consistent level of 
fluorescence. The more spread out nature of cells in the culture spiked with the 4mM NaBu 
made a qualitative visual comparison more difficult, but its fluorescence seemed to be more 
pronounced than that of the culture spiked with 2mM NaBu. These images were subjected to 
further signal intensity gating using ImageJ to only capture higher intensity fluorescence 
provided much more convincing evidence of this higher fluorescence in Figure 23. 
  
Figure 23: High Threshold fluorescence of infected cells with 2mM (left) and 4mM (right) NaBu (40x 
magnification) 
The increase in fluorescence with NaBu concentration was established at this point and it 
was the degree to which it improves the detection of the infection that needed to be investigated. 
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The factor by which the infection of the cells increased the level of fluorescence was therefore 
calculated by dividing the 12hpi fluorescence by the fluorescence in the absence of HSV.  
 
Figure 24: Percent of pixels in the image of each culture over the “high fluorescence” threshold in infected and uninfected 
HSV2012-121 Vero Cells (n=1) 
Figure 24 shows the significant increase in fluorescence resulting from infection with 
ACAM529. The background (uninfected cell) fluorescence was low at all concentrations of 
NaBu, but the addition of 4mM of NaBu increases the percentage of the imaged culture 
fluorescing brightly by a factor of 9.7. The effect on infected cells was far more significant, with 
a 25.6-fold increase in area fluorescing brightly (between 0 and 4mM NaBu). Comparing 
infected and uninfected cell fluorescence at each concentration of NaBu, it was at 2mM that the 
difference between the infected and uninfected cells’ fluorescence was the most pronounced with 
a factor of 16.9. The scale of this increase was almost twice that of the 4mM cultures in spite of 
the lower fluorescence area overall and lower intensity shown in Figure 23.  
5.4.1.4 Conclusions 
While the increase in fluorescence with increased NaBu concentration was shown for both 
infected and uninfected cells, the optimal concentration was 2mM. At 2mM NaBu the difference 
between infected and uninfected fluorescence was highest. At the same time, the percentage area 
of the images which corresponded to high intensity fluorescence was comparable to that of the 
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4mM NaBu culture. Given that the cell death was lower at this concentration (both for infected 
and uninfected cells) this level also kept the system closer to un-spiked culture conditions. Given 
the 16.9-fold increase in fluorescence that the cells displayed in the presence of the 2mM NaBu, 
there is definitely potential for NaBu spiking to improve the accuracy of EPDAs with the 
HSV2012-121 Vero cells and ACAM529 HSV line. Only one replicate was analysed for each 
condition and so further investigation is required to ascertain the true statistical significance of 
the results. 
 
  
79 
 
Chapter 6 – Viral Protein Cellular 
Co-Localization: Virus Production 
and Egress 
In this investigation, immunofluorescent staining combined with confocal microscopy 
were used to image AV529-19 Vero cells infected with the ACAM529 HSV and to examine the 
localization and co-localization of viral proteins and cellular features. The motivation for this 
work was the lack of information on the location of mature virus particles within infected cells 
which could not be reached by current harvesting methods. The localizations of individual virus 
proteins could provide important information towards this goal and locating the co-localization 
of particular proteins could point to mature virus particles within the cells. 
6.1 Background 
Capturing images of virus particles by microscopy is a difficult proposition for several reasons. 
The first and most basic of these are the scales involved. Infected host cells are roughly three 
orders of magnitude larger than the 120-200 nm virus particles they are infected with (in the case 
of HSV specifically, other viruses may be larger or smaller). It is impossible to locate HSV virus 
particles using light microscopy. Electron microscopy offers a higher resolution and can be used 
to image individual virus particles or clusters of particles within cells. Unfortunately, at this scale 
a lot of the context (in terms of location within the cell and what organelles are involved) is lost 
unless specialized correlative microscopy equipment and techniques are used.  
A method commonly employed to bypass these issues involves fluorescence staining of 
viral proteins. If a fluorescent tag can be attached to a viral protein then it can be located within a 
cell at lower magnifications using fluorescence microscopy. If the protein or set of proteins 
tagged in this way are those which indicate the presence of mature virus particles then their 
localization can be determined without the use of electron microscopy. Locating individual 
proteins rather than only whole virus particles can also yield other information which is useful 
for virology research. Since fluorescence microscopy only images fluorophores, fluorescent 
staining of major cell structural components (such as actin fibers or cell membranes) is usually 
used in conjunction with viral protein tagging to locate the host cells and their organelles. 
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Fluorescence staining of viral proteins requires the delivery of the tag directly and 
exclusively to the protein in question, all within an infected host cell. There are naturally 
occurring molecules that can be used to target and tag proteins i.e. antibodies. Antibodies are 
proteins produced naturally by B cells in vertebrates. These proteins have the ability to bind to 
foreign molecules (antigens), including viruses. This power can be harnessed and used in vitro, 
to bind to specific antigens. Combined with different fluorophores, the antibody can be used 
‘stain’ specific antigens, a process referred to as immunofluorescent staining (IS).  
 
Figure 25: Indirect and direct immunofluorescence staining 
The staining itself can be done using two methods (Figure 25), “Direct” and “Indirect” 
IS. Direct IS is the simpler but more restrictive of the two methods. The antibody targeting the 
viral protein (called the “primary antibody”) is conjugated directly to a fluorophore and a single 
staining step is required. Conjugated antibodies are expensive to develop and can only be used in 
very specific systems. The selection of fluorescence-conjugated primary antibodies is therefore 
limited and creating a new antibody of this type is often too costly for a single project. There is a 
broader selection of unconjugated antibodies commercially available which can be used in 
indirect IS. 
Indirect IS utilizes an unconjugated primary antibody and a fluorophore-conjugated 
secondary antibody. The staining is done in two steps, with a primary antibody added first to 
bind to a target, in this work, a viral protein. Once the cells have been washed of any excess 
(unattached) primary antibody, a secondary antibody, which targets a primary antibody, is added 
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to complete the tagging of the protein with a fluorophore. The secondary antibody is less specific 
and is designed to tag any antibody produced in a given source animal (anti-mouse, anti-goat, 
etc.). As long as the primary antibody is produced in the animal system that the secondary 
antibody targets, the indirect staining method can achieve similar results as direct IS without the 
need for conjugated primary antibodies.  
6.2 Determining the efficacy of primary and secondary antibodies for IS of 
infected AV529-19 cells 
The use of antibodies in IS creates some unique challenges for experimental design. The 
antibodies must be selected carefully both in terms of being able to achieve the goals set out for 
the experiment and in terms of being compatible with each other and the system being stained. 
Reviewing the literature and supplier recommendations can provide some information on the 
compatibility of the antibodies for a given system. However, since the ACAM529/AV529-19 
system is genetically modified and unique, experimental results were also required to ascertain 
the viability of various antibodies. The goal of this experiment was to stain infected Vero cells 
with potential antibodies and image the staining to determine which antibodies could be used in 
future experiments.  
Antibodies were selected based on availability from known suppliers, literature 
references of the specific products being purchased, and knowledge gained through literature 
review of the HSV virus itself. Due to the specialized nature of the experiment, only one 
conjugated primary antibody was identified. The remainder of the staining was accomplished 
using indirect IS. The conjugated antibody was anti-glycoprotein E attached to an FITC 
fluorophore, or “a-gE+FITC”. The unconjugated antibodies were also named after the proteins 
they target and were designated as “a-gB”, “a-gC”, “a-gD”, “a-ICP27”, “a-ICP5”, and “a-poly”.  
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Figure 26: Expected gene expression timing 
During infection, gB, gC, gD, and gE, which are all envelope glycoproteins, are produced 
at later stages of infection (Figure 26) and can be found at sites where virus particles become 
enveloped and bud out from the cell [2]. These proteins were targeted because co-localization of 
these proteins could indicate sites of mature virus particles. Finding them together with ICP5, 
which is a major viral capsid proteins, would be evidence of fully formed virus particles. “Poly” 
refers to a polyclonal antibody which targets the capsid proteins and other late structural 
components of HSV virus particles, much like a-ICP5. ICP27 is an essential multifunctional 
protein which could provide an earlier indication of infection (Figure 26). 
6.2.1 Determining noise levels and assessing negative controls for viral protein IS 
Controls are an essential part of any experiment, allowing the system’s background noise to be 
quantified and exposing false positive signals. In fluorescence staining, controls are even more 
important, and without them, differentiating between true signals and non-specific binding is 
nearly impossible. The IS conducted in this investigation was aimed at identifying proteins 
produced through viral infection, and so two controls were necessary: a “no infection” control to 
show non-specific binding of the stains, and a “1 hpi” control to identify any proteins from the 
infecting HSV particles which were stained.  
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With no virus present, any staining which occurred in the no infection control could be 
attributed to non-specific binding with absolute certainty. At 1hpi the infection is just beginning 
and no progeny viral proteins should have been created in significant quantities. Any signal at 
1hpi above and beyond the “no infection” background could be considered a false positive for 
this reason, as it does not represent progeny viral protein being stained. 
Three representative proteins were chosen from the full panel to determine the extent of 
the non-specific binding which could be expected. A-gE+FITC and a-Poly were both unique, 
with the former being the only direct staining antibody and the latter being the only polyclonal 
antibody used. They were included in the control experiment alongside a-ICP5, which was used 
as a representative indirect staining antibody. 
 
 
Figure 27: Infected AV529-19 cell a-Poly staining, no infection (A: no infection, B: 1hpi, 1: Cellmask (647) channel only, 2: 
488/647 channel overlap 3: Alexafluor 488 channel only)  
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Figure 28: Infected AV529-19 cell a-gE staining, no infection (A: no infection, B: 1hpi, 1: Cellmask (647) channel only, 2: 
488/647 channel overlap 3: Alexafluor 488 channel only) 
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Figure 29: Infected AV529-19 cell a-ICP5 staining, no infection (A: no infection, B: 1hpi, 1: Cellmask (647) channel only, 2: 
488/647 channel overlap 3: Alexafluor 488 channel only)  
The images in Figure 27 indicated the very high level of non-specific binding in the a-Poly 
antibody indirect staining. The no infection and 1hpi control conditions showed a high intensity 
of staining even compared to the CellMask membrane stain. The pattern made by the Cellmask 
stain (Figure 27 1A and 1B) is almost exactly the same as that in the second channel (Figure 27 
3A and 3B). It was not clear whether the primary or secondary antibody were primarily 
responsible for the non-specific signal. However, given that neither was used in combination 
with any other antibody and no other secondary antibody was available for use with the a-Poly 
this question could not be resolved within the scope of this investigation. 
Staining with a-gE+FITC also showed significant fluorescence signal in the control 
images (Figure 28). This signal (Figure 28 3A and 3B) was significantly weaker than that which 
was observed for a-Poly in Figure 27 and was observed primarily in the cell nuclei (which can be 
seen in Figure 28 1A and 1B as rounded features surrounded by higher CellMask staining). 
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Of the antibodies investigated the a-ICP5 antibody had the highest specificity. The 
AlexaFluor 488 signal in the control images (Figure 29 3A and 3B) was faint and required 
significant enhancement to be visualized. What signal was observed in these images did not 
match the CellMask signal (Figure 29 1A and 3B) as closely as it had in the case of a-Poly 
(Figure 27). These findings were positive in light of the use of a-Mouse AlexaFluor 488 
secondary antibody in the majority of the staining conducted on infected cells and validated the 
use of indirect staining in spite of the issues encountered in the a-Poly controls. None of the 
antibodies showed increased intensity or distribution of fluorescent signal in the 488nm channel 
of their 1hpi control (Figure 27, Figure 28, and Figure 29 B3) as compared to their respective 
0hpi control (Figure 27, Figure 28, and Figure 29 A3). 
6.2.2 IS antibody panel of infected cells at 6 and 18hpi  
6hpi and 18hpi time points were stained to capture events both early and late in the infection. 
Only a few of the proteins stained were expected to appear within 6 hours of infection, namely 
ICP27, gE, and potentially gB and ICP5 (Figure 26). 6hpi staining was conducted in the hopes of 
testing the stains’ lower limit of detection as well as provide insight on which antibodies may be 
suitable for early-infection work. By 18hpi all proteins were expected to have been expressed 
and visible as long as the primary antibody (and secondary where applicable) were effective.  
6.2.2.1 Infected Cell Protein 27 (ICP27) 
ICP27 is a multifunctional protein essential for viral replication. It is expressed in the 
“immediate early” (α) stages of infection and is involved in translation of viral genes [2]. It has 
also been implicated in late gene expression enhancement and progeny virus particle release 
from the extracellular surface of host cells [234]. The protein is known to be present in the 
nucleus and cytoplasm of infected cells, and to shuttle actively between the two locations [2].  
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Figure 30: Infected AV529-19 cell a-ICP27 staining (A: 6hpi, B: 18hpi, 1: Cellmask (647) and 488 channel, 2: Alexafluor 488 
channel only 3: Alexafluor 488 channel with high brightness and contrast settings)  
The staining with a-ICP27 was weaker than all of the other antibodies’ in this 
investigation. The 6hpi images in Figure 30 A showed almost no signal even with adjustment to 
brightness and contrast. ICP27 is coded for with an α or early gene, meaning that this lack of 
signal was not expected. The 18hpi signal was weak as well, barely visible in Figure 30 B2. The 
staining observed was very diffuse throughout the cells rather than focused within the cell. The 
multifunctional role of ICP27 justified some signal diffusion, but the weakness of the signal 
remained an issue in terms of using a-ICP27 for staining experiments. 
6.2.2.2 Glycoprotein B (gB) 
Glycoprotein B is a trans-membrane protein that is the product of a gene expressed in a “leaky 
late” (γ1) fashion. This means that while it was expected that the majority of the expression 
would occur after 6 hpi, some level of expression was expected earlier in the infection. gB has 
been detected as early as 2 hpi in some studies [51]. The main function of gB is fusion of the 
virus membrane with the host cell membrane on attachment through its interactions with the 
gH/gL complex as well as gD [2]. It has also been found to promote cell-to-cell fusion and 
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transmission [235], and was therefore expected to be found at cell junctions. It was also expected 
at sites of HSV envelopment and localizations of mature virus particles  
 
 
Figure 31: Infected AV529-19  cell a-gB staining (A: 6hpi, B: 18hpi, 1: Cellmask (647) and 488 channel, 2: Alexafluor 488 
channel only 3: Alexafluor 488 channel with high brightness and contrast settings). The circles indicate localizations at (by 
colour): cell outer membrane (red), envelopment sites (yellow), and cell/cell junctions (blue) 
At 6hpi, a-gB was the most successful of all antibodies used. The localizations seen were 
dispersed but not diffuse with low background noise levels (Figure 31 A). Given that gB was 
expected to be detectable within 2 hours of infection, it was not unrealistic that it could be seen 
at 6hpi. This, along with heavy gB presence at cell-to-cell junctions and outer cell membranes, 
meant that the signal was very likely to be specific to gB. The signal only grew in strength for 
the 18hpi staining of gB (Figure 31 B), with strong localizations observed at the same expected 
regions as well as in pockets within infected cells. This was consistent with glycoprotein B’s 
known function as an essential protein for viral attachment and fusion. 
6.2.2.3 Glycoprotein E (gE) 
Like other glycoproteins, gE is found on the outer membrane of mature HSV-2 particles and is 
multifunctional. Similar to gB, is connected to cell-to-cell transport [104] and has additional 
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functions in anti-host defense of the virus [2]. The gene coding for this protein is expressed 
under a γ1 promoter like that of gB, but there is no evidence to support that it could be detected 
as early as gB in the infection. Nevertheless, it was anticipated that some expression could be 
detected by 6 hpi. 
 
 
Figure 32: Infected AV529-19 cell a-gE+FITC staining (A: 6hpi, B: 18hpi, 1: Cellmask (647) and 488 channel, 2: Alexafluor 488 
channel only 3: Alexafluor 488 channel with high brightness and contrast settings). The circles indicate (by colour): cell non-
specific binding in nuclei (red) and possible non-nucleus localization (yellow). 
Staining with a-gE+FITC at 6hpi (Figure 32 A) was consistent with the 1hpi and no 
infection negative controls (Figure 28 A3 and B3) with high levels of staining in the cell nuclei 
and diffuse background noise. Given the lack of evidence for gE presence in the nucleus, this 
was likely to be non-specific staining. The low specificity of the staining made the presence of 
gE impossible to determine in Figure 32. At 18hpi the signal strength increased and several non-
nuclear localizations were observed (Figure 32 B3). These localizations were consistent with the 
known functions of gE, appearing near cell junctions and within the infected cells. The intensity 
of the positive signal reduced the effect of the diffuse background noise but did not eliminate it.  
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6.2.2.4 Infected Cell Protein 5 (ICP5) 
ICP5 is also known in the literature as viral protein (VP) 5. Transcription of its gene is controlled 
by a γ1 promoter [236]. ICP5 is a major structural component in HSV-2 viral capsids [236] and is 
known to localize at sites of capsid assembly within the nucleus. As part of the capsid, ICP5 is 
expected to spread throughout the cell with virus particle envelopment and egress at later stages 
of infection. 
  
 
Figure 33: Infected AV529-19 cell a-ICP5 staining (A: 6hpi, B: 18hpi, 1: Cellmask (647) and 488 channel, 2: Alexafluor 488 
channel only 3: Alexafluor 488 channel with high brightness and contrast settings). The red circle indicates strong 
localizations in infected cell nuclei. 
The 6hpi Alexafluor 488 signal for a-ICP5 was non-existent (Figure 33 A) which was 
expected for a protein expressed under a γ1 promoter. The 18hpi signal was strong, with very no 
brightness/contrast adjustments required. This pointed to a very high specificity of the antibody 
and validated the 6hpi results (poor antibody binding would result in weak signal in all samples). 
The majority of the staining in Figure 33 B was concentrated in the nuclei of certain cells but not 
others, which was further evidence of high specificity (otherwise all nuclei would have been 
stained). Furthermore, the non-uniform staining of infected cell nuclei was consistent with the 
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known formation of distinct occlusions at which viral DNA encapsulation occurs [2, 43, 44]. By 
18hpi the capsids were expected to be at sites of mature virus particle egress, but this was not 
reflected in the images taken (Figure 33 B3). 
6.2.2.5 Glycoprotein D (gD) 
gD is another glycoprotein involved in the fusion of virus particles to host cell membranes. It 
signals the gH/gL + gB fusion complex when a compatible receptor is detected and initiates the 
conformational changes required for fusion to begin [20]. This protein has also been implicated 
in control of host cell apoptosis [237]. The gene coding for gD is expressed under a late (γ) [2] 
promoter. gD was not expected to appear until after the 6 hpi timepoint. Like other 
glycoproteins, gD was expected to localize at sites of virus envelopment and egress within 
infected cells. No specific staining was expected in the cell nuclei given this protein’s functions. 
 
 
Figure 34: Infected AV529-19 cell a-gD staining (A: 6hpi, B: 18hpi, 1: Cellmask (647) and 488 channel, 2: Alexafluor 488 
channel only 3: Alexafluor 488 channel with high brightness and contrast settings). The red circles indicate polarized 
localizations at outer cell membranes. 
The 6hpi signal of the a-gD antibody was undetectable. The lack of non-specific binding 
in Figure 34 A2 and A3 was encouraging and the complete lack of staining was expected. The 
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staining in the 18hpi images (Figure 34 B) further established the efficacy of the a-gD stain. 
While the signal at 18hpi was not strong, it remained discernible. The protein was seen to 
accumulate near the outer cell membranes and in pockets within the cell. This along with the 
lack of staining in the nucleus was in agreement with literature for the localization of 
glycoproteins. 
6.2.2.6 Glycoprotein C (gC) 
gC is a viral protein that is expressed under a true late (γ2) promoter and was not at all expected 
to appear until the 18 hpi timepoint. The 6hpi timepoint was stained for consistency and as a 
control to ensure specificity. The distribution of gC throughout the host cell was expected to be 
the same as that of gD and gB as it too is implicated in fusion of the virus particle membrane to 
that of the host.  gC contributes by binding to heparin sulfate, an outer membrane structure found 
in all animal tissues, with a an affinity higher than that of other HSV-2 protein-receptor 
interactions [238].  
 
 
Figure 35: Infected AV529-19 cell a-gC staining (A: 6hpi, B: 18hpi, 1: Cellmask (647) and 488 channel, 2: Alexafluor 488 
channel only 3: Alexafluor 488 channel with high brightness and contrast settings). The circles indicate localizations at (by 
colour): cell outer membrane (red), envelopment sites (yellow), and cell/cell junctions (blue)  
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The 6hpi signal was effectively undetectible for gC as anticipated (Figure 35 A), while 
the 18hpi staining was visible even at lower brightness and contrast (Figure 35 B). The a-gC 
signal did not seem to co-localize with the cell nuclei or the regions with strong Cellmask 
staining, further evidence of specific binding. The gC signals seem to be localized either on the 
edges of the infected cells, or in diffuse regions within the cell which was consistent with the 
known properties of this protein.  
6.2.2.7 Polyclonal antibody against HSV-2 late structural proteins (Poly) 
The proteins stained by a-Poly were not known and so the time of expression could not be 
determined. It was know, however, that the proteins were structural in nature and so were not 
expected until mid to late infection (6-12hrs). This was based on the known expression patterns 
of HSV-2 structural proteins. Capsid proteins like ICP5 and VP23 were known to be produced 
by expression of genes under γ1 promoters, while tegument proteins like VP1-2 and VP26 are 
produced through expression of genes under a γ2 promoter [2]. However, given the poor 
specificity displayed by a-Poly in Section 6.2.1 this antibody was not anticipated to perform well 
at any time post-infection. 
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Figure 36: Infected AV529-19 cell a-Poly staining (A: 6hpi, B: 18hpi, 1: Cellmask (647) and 488 channel, 2: Alexafluor 488 
channel only 3: Alexafluor 488 channel with high brightness and contrast settings) 
The a-Poly staining in Figure 36 A and B was similar to the control images (Figure 27). 
In addition, the 6hpi staining was nearly identical in strength and distribution in the cells to that 
of the cells 18 hpi. With the continued strong mirroring between CellMask and a-Poly staining, 
all these observations pointed towards non-specific binding. The extent of the similarity between 
infected and uninfected cell staining also pointed towards very low levels of specific staining or 
expression of the proteins being targeted. 
6.2.3 Conclusions 
This investigation provided information on the interactions of a range of antibodies with the 
system being studied. Knowing what tools can be used to attain useful information can save time 
in future experiments. 1 hpi controls showed no significant differences from “no infection” 
controls for any of the antibodies tested. While viral proteins from the infecting virus may be 
present in the cells, their effect was seen to be minimal. a-Poly was the only antibody for which 
staining was deemed too non-specific for further experiments. a-gE+FITC also produced non-
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specific binding, but this was for the most part limited to the cell nuclei and did not affect the 
antibody use where direct IS is required.   
Table 3: Summary of Individual Protein Immunofluorescent Staining Results 
 Results and Findings 
Viral Protein Controls 6hpi 18hpi 
ICP27 N/A Weak, diffuse signal Weak, diffuse signal 
gB N/A Strong signal, 
locations supported by 
literature  
Strong signal, 
locations supported by 
literature 
gE Non-specific signal in 
nucleus 
Non-specific signal in 
nucleus 
Non-nucleus 
localizations present 
ICP5 Weak non-specific 
signal throughout 
No signal Very strong signal in 
infected nuclei 
gD N/A No signal Moderate strength 
signal, polarized 
localizations 
gC N/A Weak/No Signal Strong signal, 
locations supported by 
literature 
Poly Strong non-specific 
signal throughout 
Strong non-specific 
signal throughout 
Strong non-specific 
signal throughout 
 
All 5 antibodies tested, except for a-ICP27, performed relatively well at 18 hpi with good signal 
strength and staining patterns supported by literature. a-ICP27 produced no signal and was 
therefore discarded as a candidate for future work alongside a-Poly. Of the remaining 4 
antibodies, a-gB and a-ICP5 provided the strongest signal at 18 hpi with localizations which 
agreed with the literature in terms of their location relative to infected host cell features. All 
other antibodies produced weaker, but still discernible, signals at 18 hpi. At 6 hpi, only a-gB 
produced a strong and protein-specific signal. As a result, a-gC, a-gE+FITC, a-ICP5, a-gB, and 
a-gD are acceptable for future work in staining cell in late infection. Only a-gB was found to be 
useful in staining cells in early and intermediate stages of infection.  
6.3 Mature virus particle identification through co-localization of 
fluorescently tagged proteins  
Locating virus particles within infected host cell is a difficult proposition. Confocal microscopy 
and IS allow viral proteins to be identified and imaged. Unfortunately, viral proteins do not only 
96 
 
exist as part of a mature virus particle. Proteins can be found by themselves at the sites of their 
synthesis, together with other proteins being ferried around the cell, at the sites of viral egress, on 
incomplete virus particles, and on non-infectious virus-like particles. As a result, the imaging of 
a single viral protein can only be used to study that protein’s localizations. To gain more 
concrete evidence on the location of mature virus particles, more than one protein must be 
stained. 
The concurrent staining of more than one virus protein is a challenging proposition for 
several reasons. Firstly, if indirect staining is used then the antibodies must be selected very 
carefully to avoid cross-contamination of the signals. If the source animals of the two antibodies 
are the same then any secondary antibody used will bind to both equally and the signals become 
convoluted. The secondary antibodies and/or fluorophores must be selected such that their 
emission and excitation wavelengths are as far apart as posssible. This improves the ability of 
confocal microscopy to separate the signals Lastly, the antibodies must be chosen so that their 
co-localization provides valuable information. Staining multiple proteins which are expected to 
co-localize at all stages of infection does not point to mature virus particle localization. 
For this investigation, infected Vero cells were stained using a-ICP5 and a-gE+FITC to 
determine the efficacy of this co-staining for investigating the HSV/Vero cell system. Both of 
these antibodies were derived from mice, but the fluorophore-conjugated a-gE+FITC allowed 
only one secondary antibody to be used. As long as a-ICP5 and its secondary antibody were 
added before the a-gE+FITC all cross-contamination was avoided.  A co-localization of the two 
proteins had a very high likelihood of indicating the presence of complete (and hopefully 
infectious) virus particles given their roles in the assembly of HSV-2. In order to observe the 
location and condition of infected cells, they were also stained with either CellMask or 
Cytopainter Phalloidin-iFluor 647 Reagent F-actin stain. While the CellMask staining was 
significantly brighter and covered a larger portion of the cells’ surface area, Cytopainter 
obscured other signals less and outlined individual cells more neatly. 
Controls were examined first to determine the level of background fluorescence, whether 
from non-specific binding or from other sources of error. Each of the antibodies used was 
analyzed in Section 6.2 and the staining in this section used much of the knowledge gained from 
those experiments.  
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Figure 37: Infected AV529-19 cell a-ICP5, a-gE+FITC, and CellMask staining, no infection (A: no infection, B: 2 hpi, 1: All 
channels 2: a-gE+FITC staining only (488 channel), 3: a-ICP5 staining only (405 channel))  
Figure 37 A2 showed that a-gE+FITC had negligible fluorescence outside of the non-
specific nucleus staining already observed in 6.2.1 (Figure 28). a-ICP5 staining was also 
observed primarily in cell nuclei (Figure 37 A3) which indicated a possible issue for this 
protein’s staining in particular (given that as a viral capsid protein stain it was expected to be 
seen in the nucleus). Specific a-gE+FITC staining was not expected in cell nuclei and that 
staining was therefore ignored in the analysis of further images.  
The 2hpi control staining in Figure 37 B showed non-specific staining that was not 
noticeably different from the no infection control. Both antibodies showed no increase in 
prevalence due to the presence of infecting virus particles. This same observation was made in 
Section 6.2. As a result, the 2hpi control provided no additional information but did reinforce the 
findings from the controls in that section and eliminated any concerns over infecting virus 
particle protein staining. 
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Figure 38: Infected AV529-19 cell a-ICP5, a-gE+FITC, and Cytopainter staining at 20hpi (A/B: two different samples, 1: All 
channels (405, 488, 647), 2: a-gE+FITC only (488 channel), 3: a-ICP5 only (405 channel))  
Figure 38 shows the staining of cells at 20hpi. The signal for both ICP5 and gE were 
much more easily discernible than they were in the controls (Figure 28 and Figure 29). The F-
actin staining (Figure 38 A1 and B1) provided information on the state of the cells with much 
less polyhedral shapes in some cells. AV529-19 Vero cells are known to become less polyhedral 
and detach from their substrate when infected (Figure 16). The strength of both the a-gE+FITC 
and AlexaFluor 405 antibodies varied significantly between the cells which appeared infected 
and those that did not. Unfortunately, the regions in which each channel showed the strongest 
signal overlapped completely.  
While the a-gE+FITC was slightly more diffuse in its staining and maintained its low 
level of non-specific staining in cell nuclei, all other features were identical between the two 
antibodies. Given the different natures of the viral proteins being stained this observation was 
unexpected and pointed to cross-contamination in the staining or imaging. The order in which 
the two proteins were stained should theoretically have eliminated cross-contamination due to 
binding of the AlexaFluor 405 to both primary antibodies. Another feasible explanation for this 
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level of cross-contamination was leakage between the fluorescence channels during imaging. 
While the emission and excitation wavelengths of the two fluorophores were theoretically far 
enough apart for concurrent imaging (roughly a 100nm difference between the peaks for both 
excitation and emission), some level of leakage was reported with this combination of 
wavelengths [239]. 
Another concern was the low level of gE staining outside of the seemingly cross-
contaminated infected cell nuclei. The glycoprotein was expected to be localized at cell-to-cell 
junctions and throughout the host cells, and none of this was evident in the results. ICP5 was also 
seen almost exclusively (and most strongly) within the infected cell nuclei. Granted, ICP5 was 
expected to have a strong presence in the nuclei. The highly stained localizations within the 
nuclei were in line with literature pertaining to the formation of viral capsids (Section 2.1.2.2). 
Unfortunately, its absence from other regions in the cell indicated a potential issue. If the 
presence of a tegument layer or envelope prevented the a-ICP5 antibody from tagging the viral 
capsid then the goal of the experiment could not be achieved.  
6.3.3 Conclusions 
Although the non-specific binding and background noise were at an acceptable level in this 
experiment and the staining seemed to result in a strong signal, the co-staining of ICP5 and gE 
was deemed unsuccessful. The two signals (from FITC and AlexaFluor 405 fluorophores) 
overlapped precisely in all stained regions, likely indicating that bleeding of the signals between 
channels was occurring. The lack of significant staining of either protein outside of the cell 
nuclei was also an issue given that both are expected throughout the cells at later stages of 
infection. The possibility that viral capsids could not be stained once they have acquired a 
tegument and/or envelope was concluded to be the most likely cause of this issue for ICP5. 
Given this combination of issues it was difficult to properly gauge the efficacy of the a-gE+FITC 
staining alone in this investigation.   
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Chapter 7 – Development of a 
Directional Assay to Probe 
ACAM529 Egress 
In this investigation, a co-culturing (of cell lines) protocol was developed to separate infected 
and uninfected populations of cells from each other, and then observe if and how virus spread 
from one population to the other through downwards budding (Figure 39). The protocol is 
described in detail in Section 4.9. The goal of these experiments was to determine the quantity of 
infective virus particles that bud downwards (towards the membrane surface and into the well 
culture) in relation to the original infection’s MOI. The motivation for this work was the need for 
information on this particular inaccessible (to current harvesting methods) sub-population of 
virus particles which could then be in future experiments which study this system. 
7.1 Background 
In an infected cell culture, HSV spreads cell-to-cell or egresses into the supernatant before 
attachment to a new host cell [240, 78, 241]. From a manufacturing stand-point, the retention of 
virus particles within cells can reduce overall yields significantly. Accessing these viruses 
requires lysis of the cells which causes heavier contamination, and increases downstream 
processing costs. Furthermore, viruses that bud towards the solid substrate on which the cells are 
growing may be inaccessible to standard harvesting techniques. Quantifying this subset of 
progeny virus particles could inform changes to harvesting, which, in turn, could improve the 
recovery yield of virus from the process. The goal of this investigation was to establish a novel 
way of studying the preferential downwards budding of ACAM529 using materials designed for 
the co-culture of animal cells (Figure 39).  
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Figure 39: Downward budding and subsequent inaccessibility of progeny ACAM529 Virus Particles 
Co-culturing of cells is used extensively to create more realistic in vivo models of cellular 
environments [242, 243, 244, 245]. Co-culturing refers to two or more distinct cell types cultured 
together, where they are allowed to interact physically and chemically [246]. While culturing a 
single cell line is much simpler and less expensive, some processes cannot be studied without the 
additional complexity of interactions between different cell types.  
7.2 Validation of cell culture insert membrane as a valid Vero cell substrate  
Cells displayed healthy attachment and propagation on the cell culture insert membranes. It can 
be seen in Figure 40 A that the AV529-19 cells adhered to the insert membrane and formed a 
fully confluent monolayer. The cells also retained their polyhedral shape and very few 
unattached cells were observed (potentially due to the translucent nature of the membrane 
resulting in an inability to observe cells not attached to its surface). The culture appeared as 
healthy as the one grown on the cell culture plate (Figure 40 B).  
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Figure 40: Uninfected AV529-19 culture (A: Insert culture, B: Well culture) (40x magnification) 
7.3 Progression of Infection in “Insert Cultures” 
Cells cultured in tissue culture inserts did not usually show any signs of infection until 15 hpi. 
Figure 41A and Figure 41B show no cell rounding or detachment, which would be expected if 
the cells were experiencing any cytopathic effect. Since the cell monolayers were completely 
confluent prior to infection (Figure 41A), no cell replication or spread was observed (Figure 
41B-E). In fact, the small size of the cells and lack of elongation (like that which can be seen in 
Figure 40B) indicated that the density of the monolayer was higher than the minimum required 
for complete coverage of the substrate. Lower seeding density could be used in the future.  
At 15 hpi (Figure 41C) the cytopathic effect became easily discernible with cells 
rounding and becoming larger throughout the insert culture. The infection was evenly distributed 
and its effects were well synchronized in all cells infected. The infection did not seem to 
compromise the monolayer at this stage of infection.Figure 41D and E show a steady increase in 
the prevalence of virus-induced cytopathic effect. The density of the rounded cells increased and 
more were adjacent to one another. No significant gaps in the monolayers were observed even at 
20 hpi, likely the result of limited cell detachment and the high cell density. The Vero cell 
culture did not appear to be affected by the change in substrate and grew very effectively on the 
cell culture insert membranes. Infected cells responded in the same fashion as Vero cells 
growing in cell culture plates and the monolayers showed no observable gaps (plaques) by 20 
hpi. 
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Figure 41: Infected AV529-19 insert culture (A: No infection, B: 12hpi, C: 15hpi, D: 18hpi, E: 20hpi) (40x magnification) 
7.4 Infective titer reduction between primary and secondary infection 
for infected cell culture inserts  
The quantification of viral titer in cell culture insert was conducted in much the same way as in a 
plaque assay (Section 4.2). Plaques formed in the monolayer by cell death were counted by 
visual inspection to determine titer. Just as with plaque assays, the number of plaques present in 
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a given monolayer had to fall within a certain range (approximately 10-150) for the result to be 
statistically significant while also allowing the operator to differentiate between individual 
plaques. A minimum allowable MOI had to be determined for initial insert culture infection 
which would produce a number of well culture plaques within this range. In order to calculate 
this value, the fraction of the progeny virus particle population which budded downwards and 
could therefore pass through the membrane to infect the well culture had to be determined. 
Ideally, these plaques represented particles which budded through the insert membrane and were 
previously inaccessible to harvesting methods (  
Figure 42: Schematic of viral transfer and loss in the directional assay). 
  
Figure 42: Schematic of viral transfer and loss in the directional assay 
The entire experiment was conducted twice to assess the reproducibility of the results. 
These are referred to as Experiment 1 and 2 in this section. The titer of the viral stock used for 
initial infection was determined by plaque assay to be 2.4x10
6
 ± 4.8x10
5
 PFU/mL in Experiment 
1 and 2.2x10
6
 ± 3.5x10
5
 PFU/mL in Experiment 2 (n=3).  
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Figure 43: Insert culture plaques (top row 10
-3
, bottom row 10
-5
) 
The plaques in the insert and well cultures were counted whenever possible and these 
results were compared to the calculated viral titer to determine the extent to which each step of 
the cell culture insert experiment affected the titer. Figure 43 shows the plaques in the inserts of 
the 10
-3
 and 10
-5
 viral dilutions of Experiment 1. While the plaques were completely 
indiscernible from each other in the inserts infected at 1:10 dilution (10
-1
), the plaques of the 
1:1000 (10
-3
) inserts were fairly close to the range of allowable counts. Approximate counts 
(made in spite of the plaques being outside of the 10-150 countable plaque range) placed them at 
between 250 to 350 PFU for both experiments. 
Expected plaques counts were calculated based on the volume of diluted virus stock 
added to each cell culture insert, the dilution factor of the viral stock, and the titer calculated 
from the plaque assay. A mean of 2.38x10
5
 PFU was expected for the 10
-1
 insert cultures, 
2.4x10
3
 for the 10
-3
 cultures, and 2.4 for the 10
-5
 cultures (2.2x10
5
, 2.2x10
3
, and 22 PFU 
respectively for Experiment 2). While there is no way to determine how close the 10
-1
 cell 
inserts’ plaque counts were to the expected values, it was clear that the other inserts had fewer 
plaques than expected. The plaque counts in the 10
-3
 inserts were lower than those expected by 
almost an order of magnitude and the mean count in the 10
-5
 inserts was lower by a factor of 3.4 
in Experiment 1 and 3.2 in Experiment 2 (a difference of 5%). 
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While the losses in effective titer did not invalidate the experiment, they did have to be 
accounted for in later calculations. The titer was calculated again using only the plaque counts in 
the cell inserts and found to be roughly 7.0x10
5
 ± 2.0x10
5
 PFU/mL for Experiment 1 and 6.7x10
5 
± 1.3x10
5
 PFU/mL for Experiment 2. These titers were used in later calculations to ensure that 
the effects of mass transfer limitations at the initial infection stage were accounted for. 
Table 4: Well culture plaque counts (Experiment 1) 
2hpi at 10
-1
 10-1 10-3 10-5 
2 16 0 0 
2 3 0 0 
0 6 0 0 
 
Table 5: Well culture plaque counts (Experiment 2) 
2hpi at 10
-1
 10
-1
 10
-3
 10
-5
 
10 25 2 0 
11 21 2 0 
17 32 1 0 
 
The well culture plaque counts (Table 4 and Table 5) were much lower than those of the inserts. 
This was not unexpected, but did present an issue for calculations. For the first experiment, only 
the well cultures corresponding to the inserts infected at 10
-1
 showed countable plaques, with the 
inserts infected at lower MOIs producing no plaques at all.  
For Experiment 1, the 2hpi control wells contained an average of 1.3 ± 1.1 plaques (95% 
confidence interval), which was well below the plaque assay’s range of allowable counts. The 
lower limit of the 2hpi control well’s 95% confidence interval was 0.3, meaning that statistically 
speaking it could still be differentiated from an uninfected well. When compared to the titer of 
the initial infection in the 2hpi controls, the percentage of PFU that infected the well culture was 
only 5.6x10
-4 
%. 
The second experiment’s 2hpi control wells had far higher plaque counts at an average of 
13 ± 3.5 PFU. This corresponded to 5.9x10
-3
% of the initial infection of the insert. The 
significant differences between the well culture plaques of the first and second experiment could 
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not be attributed to initial infective titers, which were relatively close (a 9.8% difference in titers 
compared to a 68% difference between well plaque counts). 
The plaque counts in the well cultures corresponding to the 10
-1
 cell inserts showed a 
high degree of variability. In Experiment 1, the average plaque count in these wells was 8.3 ± 7.7 
(95% confidence interval). The lower limit was therefore well within the range covered by the 
false positives of the 2 hpi control (the lower limit was 0.6) and further calculations could be the 
result of experimental error. 
Experiment 2 well culture plaques were discernible from plaques caused and attributed to 
experimental error by a significant margin. An average plaque count of 26 ± 6.3 meant that the 
lower limit of 20 did not overlap with the upper limit of the expected experimental error of 16. 
Further calculations for the second experiment were therefore more statistically relevant than 
those of the first. 
The degree to which the PFU count decreased from primary infection of the insert 
cultures to the secondary infection of the well cultures could only be calculated using the 10
-1
 
plaque data. Since the exact plaque counts of the 10
-1
 inserts was not known, the comparison was 
done using the expected PFU counts (based on viral titer and infection volume), which was 
adjusted by the observed 3.4 and 3.2 factor drops between expected and actual insert culture 
counts (from plaque counts of inserts infected at 10
-5
) in the first and second experiment 
respectively. The result was an observed drop in plaque count by a factor of 8.4x10
3
 in 
Experiment 1 and 2.6x10
3
 in Experiment 2.  
Using the calculated factor and the upper limit of the 95% confidence interval of the 2 hpi 
control (2.4 plaques for Experiment 1 and 16 plaques for Experiment 2), the minimum infection 
titer for infecting an insert culture which would be expected to produce a statistically significant 
number of plaques was found to be 6.9x10
4
 PFU/mL for Experiment 1 and 1.3x10
5
 PFU/mL for 
Experiment 2. Using the results for Experiment 2 (the statistically significant results), the 
maximum infective titer that would produce plaques in the well cultures within the 10-150 range 
(set forth in the plaque assay protocol) was also determined. The end result was a recommended 
range of infection titers of 8.3x10
4
 and 1.2x10
6
 PFU/mL. Using the average titer of the viral 
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stock determined by plaque assay in this investigation the allowable dilution factors were 
determined to be 1.8 – 27x (or 10-0.26 – 10-1.4). 
The differences between Experiment 1 and 2 in terms of the well culture plaque counts 
could not be attributed to differences in either initial infective titer or insert culture plaque 
counts. A study of the method’s susceptibility to differences in handling should be conducted to 
determine if this could account for the rather significant variations in plaque counts observed. 
The contribution of mass transfer limitation to this variability is also not known  
. 
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Chapter 8 – Conclusion 
Using a spectrofluorometer and induced fluorescence to perform an EPDA for the rapid 
quantification of ACAM529 provided mixed results in Chapter 5 of this thesis. While the 
positive control (titration of Baculovirus in Sf9 cells) established the viability of this approach, 
the assay was required 10 days to provide accurate titers. This invalidated it as a rapid 
quantification method. In addition, the HSV2012-121 Vero cells required the addition of NaBu 
in order to enhance the expression of eGFP. This increased the difference between infected and 
uninfected cell fluorescence by 525% and should allow for EPDA using the 
ACAM529/HSV2012-121 system. 
Immunofluorescent staining of the ACAM529/HSV system provided unique insights into 
the level of expression of virus proteins and the efficacy of available tagging antibodies. a-gC, a-
gE+FITC, a-ICP5, a-gB, and a-gD were all found to be effective in binding their respective viral 
proteins at late stages of infection. a-gB was found to be uniquely capable of being detected as 
early as 6hpi, allowing for a wider range of future experiments. Tracking of mature virus 
particles through co-localization of a capsid protein and an outer envelope protein was not 
successful. Evidence pointed to bleeding of the signals between the 488 and 405 nm channels, as 
well as to a lack of capsid staining in the presence of a tegument of envelope layer. 
The results of the cell culture insert experiments provided a good starting point for the 
use of this pseudo co-culturing to study the budding of ACAM529. The wash steps and addition 
of plaque overlay media kept the level of false positive error very low (5.9x10
-3 
%) and staining 
and counting of plaques in both the insert and well cultures was used to establish rough 
guidelines for future experiments. In order to produce well culture plaques within a statistically 
significant and countable range (10 – 150 based on plaque assay protocol), a required initial 
infection titer of between 8.3x10
4
 and 1.2x10
6
 PFU/mL was calculated. 
Overall, while the initial goals of locating inaccessible localizations of ACAM529 in 
infected cells and determining the prevalence of downward budding were not met, the 
experiments conducted provided useful information on the system studied and form a solid basis 
for ongoing research on this topic. 
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Chapter 9 – Recommendations 
Based on the findings in this thesis, it is recommended that future work on the optimization of 
ACAM529 yield and localization of inaccessible virus particle sub-populations focus on indirect 
quantitative methods. While direct imaging of the viral localizations seemed like the more 
straightforward approach, it proved more problematic and less useful than anticipated. On the 
other hand, those methods which probed the system indirectly (namely the cell culture insert 
protocol, induced fluorescence with NaBu enhancement, and even immunofluorescent staining 
of individual viral proteins) provided useful and often more quantitative information. 
While certain features of both the virus/cell system and the fluorescent tagging prevented 
mature virus particles from being located, individual virus proteins were imaged effectively. IS is 
therefore recommended as a method for studying variations in viral protein expression, both in 
terms of expression strength and the proteins’ distribution within the host cell. Studying 
glycoproteins associated with cell-to-cell transmission was of particular interest since reducing 
this mode of transmission could increase budding into the supernatant. This could then improve 
the overall yield of virus particles in production processes. In a similar vein, the effect of Dextran 
Sulfate could be studied with the use of IS of individual glycoproteins and lend further aid to 
improving virus production. 
While the cell culture insert experiments showed great promise for the study of virus 
budding, several properties of the system remained undefined. Before the protocol is used to 
draw conclusions about the cell/virus system, it is recommended that the mass transfer effects are 
investigated. Tracking the passage of virus particles through membranes of different pore sizes 
could yield information on the limitations of passage through a membrane imposes on the 
system. Similarly, the direction in which the infection travels can be reversed by adjusting the 
protocol and infecting the well cultures instead of the insert cultures. The quantification of 
plaques in the insert cultures could then provide an indicator of the importance of Brownian 
motion. Once the system is better understood, any attempts to manipulate or change virus 
budding could utilize the cell culture insert protocol to quantify the changes which occurred. 
Incorporating the quantification directly into the experiment decreases the opportunity for error 
and reduces the impact of virus instability on titer calculations. 
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